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Give Them What They Want?

The Permissibility of Pediatric Placebo-Controlled
Trials Under the Best Pharmaceuticals for
Children Act
Holly FernandezLynch, JD., M.Bioethics*

INTRODUCTION

Despite their similar appearance, children1 are not just miniature adults.
They experience different thought processes, are given different legal rights
and responsibilities, and are even cared for by their own medical specialty,
pediatrics. For years, however, these differences have been largely ignored
in the area of pharmaceutical development, leaving children to be treated as
though they truly were just smaller versions of their adult counterparts.
Crushing half of a tablet of an adult's drug into applesauce for a five-yearold has become the norm for many parents. However, this tactic, often
recommended by pediatricians who lack a better alternative, can lead to
disastrous results or no result at all when the dose or drug is ineffective for
children.
The reasons for this lack of information are many and varied, but the
main problem has been the lack of an internal incentive within the
pharmaceutical industry to develop and test drugs specifically for pediatric
indications. Recognizing this problem, the Food and Drug Administration
(FDA) and Congress recently took two important steps in the right direction
after several unfruitful attempts at improvement since the 1960s. The
"carrot-and-stick" combination of the Best Pharmaceuticals for Children
Act (BPCA) and the Pediatric Research Equity Act (PREA) will increase
* J.D./M.Bioethics, University of Pennsylvania. Academic Fellow (2006-2008), Petrie-Flom
Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School. Thank
you to Ted Ruger for providing helpful guidance and thoughtful suggestions on this and
other projects.
1. This article will use the term "child" to refer to non-adults from birth to the age at
which their bodies metabolize and react to drugs in the same way as fully-developed adults
and at which they are able to legally (and developmentally) provide consent for medical care
and research enrollment.
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much needed research into the use of new and currently marketed drugs in
children. However, with this increase will come a plethora of ethical
difficulties associated with conducting pediatric studies. The FDA's
specific requests for legally and morally questionable placebo-controlled
pediatric trials of drugs used to treat obsessive-compulsive disorder (OCD)
and depression will only further complicate these issues.
Placebo-controlled trials compare an experimental drug with an inactive
substance designed to look and taste like the experimental drug, often called
a dummy pill. When conducted with adult populations, these trials are
generally accepted so long as subjects give their informed consent for
enrollment and are not denied an effective life-saving therapy. In contrast,
pediatric subjects are developmentally and legally incapable of providing
informed consent and thus require more protection from abuse and
exploitation in research. Still, using placebo controls with children is not
ethically prohibited, and those who recognize the dire need for pediatric
research generally concur that placebo arms can be used in some narrowly
constrained circumstances-the question is whether the FDA's requests
meet these criteria.
Physicians already routinely prescribe the drugs at issue for pediatric
treatment of OCD and depression. While some drugs have been approved
for these indications in children through the written request system
established by the BPCA, their recent association with increased suicidality2
when used in the pediatric population has essentially returned the treatment
of these disorders in children back to square one. New and existing
pediatric OCD and antidepressant drugs will need to undergo rigorous
safety tests that focus on this particular concern. However, because even
the currently approved treatments have not been proven safe with regard to
suicidality, clinical equipoise between these drugs and placebo will exist
and active-comparator or add-on studies will be impossible. Therefore, the
placebo controls requested by the FDA will likely be legally approvable,
ethically permissible, and practically necessary to re-determine the safety of
these drugs for children.
Once safety is re-established for even a single drug effective for OCD or
depression in children, the use of placebo controls becomes objectionable
for studies of other drug treatments for these indications as a safe and
effective alternative will be available. In that situation, the question should
not be whether a new drug is better than nothing, but rather, whether a new

2. Suicidality is a broad term that "appears to include [suicidal] ideation, self-harm, and
actual suicide attempts." David Brent & Boris Birmaher, Letter to the Editor, British
Warnings on SSRIs Questioned, 43(4) J. AM. ACAD. CHILD & ADOLESCENT PSYCHIATRY
379, 379 (2004).
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drug is better than the treatment currently available to pediatric patients.
Importantly, placebo controls cannot answer this question.
Some
commentators argue that existing safe and effective treatments can be
withheld for research on drugs intended to treat relatively mild conditions
because denial of that treatment for the duration of the study would not
harm the subject in any serious or permanent way. The FDA appears to
accept this reasoning, requesting placebo-controlled studies of OCD drugs
and antidepressants, but not for drugs used to treat more severe diseases like
cancer or HIV.
While the distinction between mild and serious conditions may be
justifiable in adults who are able to personally consent to enrollment in a
placebo-controlled study and effectively refuse proven treatment, children
are incapable of making such reasoned decisions and must rely on the
substituted consent of their parents. Based on the best interest standard of
proxy decision-making, parents should not be able to enroll their children in
placebo-controlled trials for even mild conditions when a safe and effective
alternative exists; it is in no child's best interest to continue needlessly
suffering, from a headache or something far more serious. Further, even
assuming that this mild/severe distinction holds for pediatric subjects, it is
not clear that childhood OCD and depression should be categorized as mild
conditions.
As this article will demonstrate, however, this ethical
discussion may be moot because placebo-controlled studies denying
pediatric subjects safe and effective treatment will not likely be legally
approvable under an appropriate application of the risk categories
established by federal regulations to protect children in research.
Part I of this article will explain the need to test drugs in pediatric
populations. Part II will outline the major reasons that this sort of testing
has not occurred in the past. Part III will briefly describe two important
initiatives launched by Congress and the FDA in hopes of reversing this
trend, including a program through which the FDA has made specific
requests for pediatric trials. Finally, Parts IV and V will apply legal and
ethical analyses, respectively, to the FDA's requests for placebo-controlled
studies of drugs to treat OCD and depression in children. While these
requests may be currently acceptable, once current suicidality concerns are
overcome and safe and effective alternatives become available, the placebo
arms of these trials will be both legally and ethically objectionable and must
be replaced with active controls.
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PART I-WHY Do WE NEED TO TEST DRUGS ON CHILDREN?

A. Lack of Information About PediatricPrescribing
The American government has made a
general policy determination, under Federal law governing drugs and
medical devices, that proof of safety and effectiveness generally requires
substantial human subjects research. Federal law generally finds even the
longstanding use of drugs or medical devices by physicians, and the
general view of physicians that such 3are safe and effective, as insufficient
to meet federal regulatory standards.
Unfortunately, this "longstanding use" and "general view," combined with
evidence of adult safety and efficacy, often constitute the only information
available to pediatricians. Doctors currently lack adequate dosing, safety,
and efficacy data regarding pediatric use of at least sixty-five percent of
drugs prescribed to children. Further, a pediatric patient's age directly
correlates with the availability of information regarding pediatric
prescribing, with the least data available for the youngest children.
This paucity of information leaves doctors with no choice other than offlabel use of medications that have only been approved for adult
populations.
While such prescribing practices are legally and
professionally permitted, widespread off-label use of drugs can be

3. David M. Smolin, NontherapeuticResearch with Children: The Virtues and Vices of
Legal Uncertainty,33 CUMB. L. REv. 621, 627 (2002/2003).
4. Allecia Vermillion, Information Lacking on Antidepressants' Effects, BUCKs COUNTY
COURIER TIMEs, Apr. 26, 2004, at 3A, available at 2004 WLNR 17314063. See also Am.
Acad. of Pediatrics, Committee on Drugs, Guidelinesfor the Ethical Conduct of Studies to
Evaluate Drugs in Pediatric Populations, 95 PEDIATRICS 286, 286 (1995) (noting that in
1991, 81% of the drugs in the Physician's Desk Reference contained a disclaimer warning
that use in children had not been determined safe or effective or restricting use to certain age
groups);
Rosemary
Roberts,
What's
So
Special
About
Children?,
http://www.fda.gov/cder/pediatric/presentation/tox-pedsnov2001/tsldOOl.htm (last visited
Sep. 2, 2006) (estimating that physicians lack information regarding the pediatric use of
about 75% of prescription medications).
5. Rosemary Roberts et al., PediatricDrug Labeling: Improving the Safety and Efficacy
ofPediatricTherapies, 290(7) J. Am. Med. Ass'n. 905, 905 (2003). Notably, this problem is
not unique to the United States: data demonstrates that the majority of drugs approved for
adults have not been approved for children in the United Kingdom, Australia, or New
Zealand, and presumably many other developed countries around the world. Joanne Grieve
et al., Effect of the PediatricExclusivity Provision on Children's Access to Medicines, 59(6)
BRIT. J. CLINICAL. PHARMACOLOGY. 730, 730 (2004).
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dangerous, or at least inefficacious.6 Physicians are forced to estimate the
appropriate pediatric dosage based on weight alone, guess about possible
adverse effects, 7 and hope that the drug formulation available for adults is
amenable for use in children. 8 Without appropriate prescribing information,
doctors may withhold potentially helpful medicines for fear of their
unintended and damaging consequences.
Alternatively, doctors may
prescribe medicines that have no effect on the condition in children at all.
Both practices result in under-treatment of pediatric illness. 9 Of course, a
worse result is that the prescribed drugs have toxic or other detrimental
effects on pediatric patients that are not witnessed in adult populations.'°
Rather than withhold drugs with no approved pediatric indication
altogether, physicians often recommend a milder dose than that prescribed
for an adult patient, resulting in a trial-and-error mini-experiment every
time these treatments are given to children. I" While some commentators
believe that conducting drug tests on pediatric subjects is unethical, 2 it
essentially occurs in pediatricians' offices every day. Moreover, providing
drugs that have not undergone appropriate testing on children may pose
more significant ethical problems.13 Not only is this experimental in itself,
but it is research without informed consent, not approved by federal
regulations, and lacks a design capable of providing useful data that will
improve future pediatric prescribing practices. 14 Off-label use as practiced
6. Smolin, supra note 3, at 629. Although these concerns may confront off-label use in
adult patients as well, the situations are distinguishable. With adults, the drugs have at least
been tested and approved by the FDA for some indication, whereas for children, there has
been no such testing and approval for the purposes of this article. Id. at 628.
7. Lauren Hammer Breslow, Note, The Best Pharmaceuticalsfor Children Act of 2002:
The Rise of the Voluntary Incentive Structure and Congressional Refusal to Require
PediatricTesting, 40 HARV. J. ON LEGIS. 133, 146 (2003).
8. Christopher-Paul Milne, Exploring the Frontiers of Law and Science: FDAMA "s
PediatricStudies Incentive, 57 FOOD & DRUG L.J. 491, 493 (2002) [hereinafter Exploring the
Frontiers].
9. Roberts, supra note 4; Roberts et al., supra note 5, at 905.
10. Roberts, supra note 4.
11. Id; Roberts et al., supra note 5.
12.

See, e.g., PAUL RAMSEY, THE PATIENT AS PERSON: EXPLORATION IN MEDICAL ETHICS

11-12 (1970) (arguing that children should never be involved in research unless all other
remedies have failed to relieve their grave illness and the experimental intervention has a
chance to further the child's own recovery).
13. Jane E. Henney, Comm'r of Food and Drugs, U.S. Food and Drug Administration,
Pediatrics in the New Millennium: Compelling Issues in Public Policy - Increasing Pediatric
Access to Medical Therapies, Remarks at the Pediatric Academic Societies and American
Academy of Pediatrics Joint Meeting (May 15, 2000), http://www.fda.gov/oc/speeches/2000/
pediatricacademic.html (last visited Sept. 2, 2006).
14. Am. Acad. of Pediatrics, supra note 4, at 286-87; see Roberts et al., supra note 5, at
905 (noting the experimental nature of off-label drug prescribing in children and its inability
to accrue data in a scientifically rigorous manner in order to build knowledge for the future);

Published by LAW eCommons, 2007

5

Annals of Health Law, Vol. 16 [2007], Iss. 1, Art. 5

Annals of Health Law

[Vol. 16

today imposes risks on individual children without any potential to benefit
the entire population.
B. Inability to Extrapolatefrom Adult Data
At this point, one question is obvious: if adequate safety and efficacy
data exist for adults, as it must for a drug to be on the market at all, why is
this data insufficient to support use in the pediatric population? The answer
is that in certain circumstances, extrapolation from adult data may be
perfectly appropriate. For the most part, however, children are so
physiologically different from adults that physicians cannot freely assume
that they will react similarly to pharmaceutical agents. When dealing with
diseases and conditions that afflict both children and adults,
pharmacokinetic15 and pharmacodynamic 16 studies may show significant
resemblance in the way a drug is metabolized by both groups of patients.
Such studies may also indicate that the disease processes themselves are
alike in adults and children. 17 In these relatively uncommon situations,
extrapolation from adult studies may be permissible, but even when the
pediatric disease and drug responses are virtually identical to those
occurring in adult patients, research in children may still be necessary to
develop "age-appropriate formulations [such as dissolvable tablets or liquid
varieties] that allow the accurate, safe, and palatable administration of
medicines to children of a wide
range of weights and with a wide range of
1' 8
developmental characteristics."

and Roberts, supra note 4.
15. Pharmacokinetics refers to "the action of drugs in the body over a period of time,
including the processes of absorption, distribution, localization in tissues, biotransformation,
and excretion."
RICHARD SLOANE, SLOANE-DORLAND ANNOTATED MEDICAL-LEGAL
DICTIONARY 406 (Supp. 1992).

16. Pharmacodynamics refers to "the study of the biochemical and physiological effects
of drugs and the mechanisms of their actions, including the correlation of actions and effects
of drugs with their chemical structure; also, such effects on the actions of a particular drug or
drugs." Id.
17. "Pharmacokinetics studies are performed to learn how a living organism (e.g.,
experimental animal) handles a foreign substance like cancer, i.e., the rate of uptake,
distribution and excretion of the substance, and the metabolites formed in the organism
following exposure." Id.
18. INST. OF MED., ETHICAL CONDUCT OF CLINICAL RESEARCH INVOLVING CHILDREN 66
(Marilyn J. Field & Richard E. Behrman, eds., 2004). See also Carol Ballentine, Taste of
Raspberries, Taste of Death: The 1937 Elixir Sulfanilamide Incident, FDA CONSUMER
MAGAZINE, June 1981 at 18, 18-21, available at http://www.fda.gov/oc/history/elixir.html
(last visited Sept. 2, 2006) (discussing the Elixir Sulfanilamide disaster in which the
manufacturer failed to conduct safety tests of a new formulation of an effective drug, and
thus did not discover that the chemical used to create the new formulation, normally found in
antifreeze, is a deadly poison).
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Usually, pediatric patients present with child-specific diseases not found
in adults at all, or they respond differently than adults to the very same
interventions.' 9 For this reason, extrapolation from adult data will often not
suffice to protect pediatric patients.20 Children are not simply lighter adults,
so weight-based dosage of adult medications is frequently inappropriate. In
fact, "children may metabolize or absorb drugs at a different rate from
adults, and therefore a suitable dose is difficult to estimate from the size of
the children., 21 Pediatric patients have different physiology, body size and
composition, growth and development, cognitive and motor function, and
special organ system maturation, each of which can impact drug disposition
and action in the body and create different outcomes from those seen in
adults. 22
"Antihistamines and alcohol, for example, two common
ingredients in cold medications, can have adverse effects on young patients,
causing excitability or excessive drowsiness. Some drugs, like aspirin, can
cause serious
illness or even death in children with chickenpox or flu
' 23
symptoms.

Several recent examples demonstrate the need for independent pediatric
research rather than reliance on adult data alone. For example, in tests of
Straterra,a drug used to treat attention-deficit hyper-activity disorder, five
out of 1,357 pediatric subjects in the experimental arm of the study reported
having suicidal thoughts.24 That number becomes increasingly alarming
considering how many thousands more children might take the drug outside
of the research context. Notably, none of the 851 subjects receiving
placebo reported a similar effect.25 This finding was particularly important

because no evidence of increased suicidality occurred among adults taking
the drug.26 Researchers suspect a similar phenomenon in pediatric patients
19. Carrie Fisher & Thomas G. Keens, Participation of Children in Research, 26
WHITTIER L. REV. 823, 831 (2005); INST. OF MED., supra note 18, at 58.
20. Joseph T. Flynn, Ethics of Placebo Use in Pediatric Clinical Trials: The Case of
Antihypertensive Drug Studies, 42(5) HYPERTENSION 865, 866 (2003); Michelle Meadows,
Drug Research and Children, 37(1) FDA CONSUMER MAGAZINE, Jan.-Feb. 2003 at 12, 13.
21. Interview by Lawrence Bachorik with Paula Botstein, Deputy Director, FDA's
Office of Drug Evaluation I, Why FDA is Encouraging Drug Testing in Children, FDA
CONSUMER
SPECIAL REPORT (Jan.
1995), http://www.fda.gov/fdac/special/newdrug/
kidmed.html.
22. Roberts, supra note 4; Am. Acad. of Pediatrics, supra note 4, at 286.
23. Rebecca D. Williams, How to Give Medicine to Children, 30(1) FDA CONSUMER 6,
8-9 (Jan.-Feb. 1996) (also noting "[s]ome barbiturates, for example, which make adults feel
sluggish, will make a child hyperactive. Amphetamines, which stimulate adults, can calm
children").
24. John Lumpkin, FDA Warns of Suicidal Thoughts Linked to ADHD Drug, PHILA.
INQUIRER, Sept. 30, 2005, at A6.

25.
26.

Id.
Id.
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suffering from major depressive disorder, OCD, and other psychiatric
problems who have been treated with selective serotonin reuptake inhibitors
(SSRIs) approved for use in adults.2 7 The major physiological and
developmental differences between adults and children, combined with
will benefit
these examples, demonstrate that children, as a class of patients,
28
significantly from research done in the pediatric population.
PART I1-WHAT ARE THE GENERAL PROBLEMS ASSOCIATED WITH
CONDUCTING RESEARCH IN CHILDREN?

Given the obvious need for pediatric research discussed above, the
glaring lack of information in this field may be perplexing. After all, it
seems as though the pharmaceutical industry would jump to meet this
demand. If manufacturers conducted the studies, they could gain FDA
approval for pediatric indications, market those uses, and reap revenue
greater than that generated by off-label prescribing alone. However, for a
variety of reasons, drug companies have largely decided that pediatric trials
are far more trouble than they are worth.
A. Ethical Concerns

In recent decades, children have been routinely excluded from research
following some serious historical abuses.29 Unfortunately, that protective
attitude went too far and helped foster the current situation in which

information on pediatric prescribing is virtually non-existent. 30

As

27. FDA, FDA Public Health Advisory: Suicidality in Children and Adolescents Being
Treated With Antidepressant Medications, Oct. 15, 2004, http://www.fda.gov/cder/drug/
antidepressants/default.htm (last visited Sept.. 2, 2006) (explaining that the increase in
suicidality was discovered through placebo-controlled studies of SSRIs in pediatric subjects
and resulted in a "black box" labeling change for many antidepressants); this problem will be
addressed in more detail below, in Part IV.
28. Fisher & Keens, supra note 19, at 832.
29. Breslow, supra note 7, at 136-38. Institutionalized children were often exploited by
investigators because there were no parents to deal with and the institutions provided nicely
controlled scientific environments in which to perform experiments. Id. See also Tom L.
Beauchamp & Ruth R. Faden, History of Informed Consent, 3 ENCYC. OF BIOETHIcs 1271,
1274-75 (Stephen Garrard Post, ed., 3rd ed. 2004) (discussing the 1956 Willowbrook study
in which newly admitted patients in an institution for mentally disabled children were
purposefully infected with hepatitis in order to conduct research in hopes of finding an
effective prophylactic agent).
30. Fisher & Keens, supra note 19, at 827-31; Jennifer Rosato, The Ethics of Clinical
Trials: A Child's View, 28 J.L. MED. & ETHICs 362, 362 (2000). "Until a few years ago, the
prevailing view was that children should not be participants in clinical research trials
because children were incapable of consenting to such nontherapeutic interventions and are
particularly vulnerable to abuse." Id. The concern about using institutionalized children is
still present, as demonstrated by the recent public outcry over the enrollment of New York
City foster children in Phase I and II HIV drug trials. Alliance for Human Research
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commentators have begun to recognize the need for a more moderate
approach, the question has moved from whether children should participate
to when and how they should be enrolled in clinical trials.31 With this shift,
pediatric research has raised two important
ethical concerns: lack of
32
capacity to consent and conflict of interest.
First, children are unable to consent to their own participation in
research.33 Children lack the facility to fully understand the potential risks
and benefits of research, or what that research entails. 34 These are the most
basic elements of informed consent. Further, emotional and cognitive
development, level of autonomy, and dependence on the influence of their
families all impede a child's self-determination. 5
In fact, most
commentators recognize that, unlike adults, children usually lack the legal
right and the intellectual and emotional maturity to consent to research
participation on their own behalf. Their vulnerability demands special
consideration from researchers and policymakers and additional protections
beyond those provided to mentally competent adult participants in
research.36
A child's inability to make decisions creates a need to obtain both
parental permission for and child assent to the conduct of pediatric
research. 37 The capacity problem also raises concerns about the level of
risk to which pediatric subjects may be exposed, an issue generally solved
by the informed consent process for adults.38 These additional complexities
are enough to scare some sponsors away.39
Additionally, given the potential conflicts of interest among parents,
researchers, and institutional review boards (IRBs), reliance on these
individuals and bodies for decision-making may be insufficient to protect
Protection, NGO Probe to Look at Foster Kids in AIDS Trials-NYC, Apr. 23, 2005,

http://www.ahrp.org/infomail/05/04/23a.php.
31. Rosato, supra note 30, at 362.
32. See, e.g., FDA, GUIDANCE FOR INDUSTRY: Ell CLINICAL INVESTIGATION OF
MEDICINAL PRODUCTS IN THE PEDIATRIC POPULATION 12-14 (Dec. 2000), available at
http://www.fda.gov/cder/guidance/4099fnl.pdf (discussing generally the ethical issues in
pediatric studies, such as the role of the Institutional Review Board, subject recruitment,
consent and assent, and minimizing risk and distress).
33. This issue will be discussed in more detail with regard to the ethics of placebocontrolled pediatric studies, infra Part V.A.3.c.
34. Meadows, supra note 20.
35. Benjamin S. Wilfond et al., Ethical Issues in Conducting Behavioral Genetics
Research: The Case of Smoking Prevention Trials Among Adolescents, 6 J. HEALTH CARE L.
& POL'Y 73, 76 (2002).
36. INST. OF MED., supra note 18, at 28.
37. See the discussion of assent and permission, infra Part V.A.3.c.
38. This issue will also be elaborated upon below in Part V, infra.
39. Meadows, supra note 20.
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children from abuse in the research setting. 40 The psychological effects of a
child's disease on his or her whole family can play a detrimental, if
inadvertent, role in preventing parents from choosing what is truly in the
best interest of their sick child.41 Specifically, monetary inducements could
42
sway parents to expose their children to greater risks than are appropriate.
In addition, researchers may have financial or professional interests at odds
with the individual child's welfare,43 and IRBs can face conflicts between
reviewing the work performed by their colleagues and encouraging "cutting
Of course, these latter concerns apply in
edge" research at their institutions.
44
adult research studies as well.
While these ethical issues certainly render pediatric research more
complicated and burdensome for clinical trial sponsors, other practical
barriers and disincentives in this area more fully explain the lack of
adequate research on drugs for children.
B. PracticalConcerns
Perhaps the most important reason the pharmaceutical industry has failed
to conduct adequate pediatric research is that for years it simply lacked any
economic incentive to do So. 45 The pharmaceutical industry operates as a
for-profit model for commercial purposes and can be expected to make
decisions driven by financial interest. 6 In this context, the pediatric
population offers small sales potential compared to the adult market,47 and
until recently, manufacturers did not need pediatric trials for FDA
approval.4 8 Sponsors seek to place products on the market quickly to
recoup their research investment and turn a profit, so they simply chose to
conduct the less complex and less regulated adult studies necessary for
FDA approval. Sponsors had little remaining incentive to conduct studies

40. Leonard H. Glantz, Research with Children, 24 Am. J.L. & MED. 213, 218-19
(1998); See, e.g., Rosato, supra note 30, at 363.
41. Glantz, supra note 40, at 218-19.
42. Id.
43. Id.
44. See Rosato, supra note 30, at 363.
45. Exploring the Frontiers,supra note 8, at 491-93.
46. Drug & Device: A Prescriptionfor Better Drug Trials, 41(3) TRIAL, Mar. 2005, at
54, 56.
47. Exploring the Frontiers, supra note 8, at 493; Michael S. Labson, Pediatric
Priorities: Legislative and Regulatory Initiatives to Expand Research on the Use of
Medicines in PediatricPatients,6 J.HEALTH CARE L. & POL'Y 34, 35 (2002).
48. The 1998 FDA Pediatric Rule and the 2003 Pediatric Research Equity Act attempted
to address this loophole, hoping to induce market incentives that had been previously absent.
These government interventions are discussed infra Part III.C.
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in children, other than the ability to openly market pediatric uses to
physicians. 4
Along with this economic non-incentive for pediatric research comes an
economic disincentive: the industry's product liability 5° and public relations
concerns.5 If manufacturers do not label and market drugs for use in
children, they might have a better chance of avoiding liability for adverse
reactions in pediatric patients, even though the drug may still be prescribed
to children through off-label use.52 While this strategy begs questions of
ethics and efficacy, given the fact that manufacturers might still be held
liable if they were aware of the off-label use resulting in problems or
illegally promoted that use,53 for manufacturers it might be less expensive
to risk liability from off-label use than to risk liability and conduct the
studies needed for pediatric indications. In addition, the possibility for offlabel use in children may lead manufacturers to avoid pediatric research and
marketing entirely to escape disastrous financial and public relations
consequences if the studies were conducted unethically or harmed the child
subjects. Children make very sympathetic victims, even if researchers and
sponsors did nothing wrong.54
Pediatric research poses other practical problems that would remain even
if off-label prescribing practices were prohibited. First, there is a shortage
of clinical investigators trained in the nuances of pediatric research 55 and it
is very difficult to enroll child subjects.56 As noted above, the market for

49.

Exploring the Frontiers,supra note 8, at 493.

50. For examples of the sort of claims brought against manufacturers for pediatric uses,
see the discussion of the SSRI litigation at http://www.sskrplaw.com/adhd/ (last visited Sept.
10, 2006).
51. See Exploring the Frontiers,supra note 8, at 491.
52. Breslow, supra note 7, at 142 ("[Tlhe pharmaceutical industry generally sought to
avoid pediatric liability by neither labeling nor marketing drugs for children.").
53. See, e.g., Proctor v. Davis, 682 N.E.2d 1203, 1216 (I11.App. 1997) (finding that
there was sufficient evidence of willful and wanton misconduct to justify punitive damages
against a drug manufacturer that failed to warn physicians of the adverse effects associated
with a particular off-label use that it was aware of and actually promoted through financial
and technical assistance to doctors, as well as by helping to create a body of literature touting
the particular off-label use).
54. See Ferdinand D. Yates, Jr., Consent Process May Not Be Adequate in Medical
Studies Involving Children, BUFFALO NEWS, May 29, 2005, at F2; Clinical Trials: House
Panel ConsidersProtectionsfor Foster Children, AM. HEALTH LINE, May 19, 2005; Deepti
Hajela, AIDS Trials Elicit Outrage,ALBANY TIMES UNION, May 6, 2005, at B3, available at
2005 WLNR 7226438; Glenn Thrush, Probe Demanded in Kid Drug Trials, NEWSDAY, Apr.
25, 2005, at A14, available at 2005 WLNR 6427329 (all discussing the controversial
pediatric HIV research that recently came to light in New York City, introduced supra note
30).
55. Exploring the Frontiers,supra note 8, at 493.
56. Id. at 491.
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pediatric medications remains comparatively small, which is in part because
children as a group are relatively healthy. This size does not mean that
children do not need pharmaceuticals; instead, the small numbers of
pediatric patients with any particular disease make finding subjects to
recruit difficult. 57 In fact, for every fifty pediatric subjects screened for
participation in a given study, usually only one will actually be enrolled.58
The fact that many parents are unwilling to enroll their children in research,
due to its risks and unpredictability, further compounds the shortage. 59
Even if appropriately qualified investigators are found and a sufficient
number of subjects are enrolled, several other difficulties arise with regard
to the study itself. Pediatric research involves a more pronounced risk of
compliance failure than research with adult subjects because the
formulation of the drug being tested might be hard for children to swallow
or generally unpalatable. 60 To ease administration and help parents follow
the study protocol, the sponsor may need to develop pediatric formulations
from scratch, adding a potentially significant expense. 61 Those conducting
the trial may also face "difficulty in determining and measuring endpoints
in children. ''62 Many studies, particularly those involving drugs for pain or
psychiatric disorders, have no clear physical indicators of efficacy
observable by the investigators, who must instead rely on self-evaluation by
subjects. 63 Objectivity concerns related to self-evaluation are further
exacerbated in pediatric studies, because children must clearly explain how
they feel in a way that can be operationalized for data comparison.
Finally, these practical considerations are multiplied because performing
only one additional study in children as a follow up to adult trials will not
suffice. The pediatric population is diverse and ranges from neonates to
toddlers, to children, to adolescents. Each of these subgroups might react
differently to a given drug. 64 Thus, sponsors potentially need to conduct
several distinct studies to obtain all the information that doctors need to
treat these groups. 65 These factors impact both enrollment and study
57. Labson, supra note 47, at 35.
58. Christopher-Paul Milne, PediatricResearch: Coming ofAge in the New Millennium,
6 AM. J. OF THERAPEUTICS 263, 269 (1999) [hereinafter Coming ofAge].
59. See Breslow, supra note 7, at 144.
60. Id. at 272.
61. See Labson, supra note 47, at 35-36 (stating that the disincentives for conducting
pediatric research can be significant, such as the difficulty associated with developing a drug
formulation specifically for pediatric use, particularly when pharmaceutical companies are
allocating their limited research dollars).
62. Henney, supra note 13.
63. Labson, supra note 47, at 36.
64. INST. OFMED., supra note 18, at 61.
65. Id.
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design, which can make pediatric studies "frustratingly and necessarily
slow because safety must be assured, controls must be in place, and
scientific conduct must be professional. 66 In light of these ethical and
economic considerations, for years the pharmaceutical industry made the
logical choice to focus almost entirely on research and development for
adult drugs.
PART III-WHAT HAS THE GOVERNMENT DONE TO ADDRESS THE
DOUBLE-EDGED SWORD OF PEDIATRIC RESEARCH?

It makes economic, legal, and ethical sense to begin clinical trials in
adult populations,6 7 but until the past decade, drug companies have lacked
any internal incentive to extend research into pediatric subgroups after
gleaning important information from adult studies. However, "[t]here is a
moral imperative to formally study drugs in children so that they can enjoy
equal access to existing as well as new therapeutic agents." 68 In accord,
government intervention has necessarily recalibrated industry incentives.
Several attempts were made to accomplish this feat and balance protective
exclusion of children against protective inclusion in pharmaceutical
research. 69 However, only the most recent attempts directly addressed the
root of the problem and come closer to realizing the ultimate goal of
improving the amount of information available to pediatric prescribers.
A. HistoricalInterventions
The 1962 Kefauver-Harris Drug Amendments to the Food, Drug, and
Cosmetic Act added the current regulatory requirement of efficacy of new
drugs to existing safety standards. 70 However, this legislation neither
required nor induced pediatric research in any way: sponsors of applications

66. Yates, supra note 54.
67. The official view of the American Academy of Pediatrics is that investigators "must
strive to obtain as much information as possible about the safety and efficacy of the drug
under study before enrolling children as subjects." "In most cases, studies in children should
be preceded by initial clinical trials in adults to provide preliminary pharmacokinetic, safety,
and efficacy data. In some instances drugs intended to treat specific diseases that primarily
or exclusively occur in children may be studied initially in children." Am. Acad. of
Pediatrics, supra note 4, at 287.
68. Id. (emphasis omitted).
69. Fisher & Keens, supra note 19, at 832; See also Loretta M. Kopelman, Group
Benefit and Protection of Pediatric Research Subjects: Grimes v. Kennedy Krieger and the
Lead Abatement Study, 9 ACCOUNTABILITY RESEARCH 177, 177 (2002) [hereinafter Group
Benefit] (explaining "[t]he problem is that with too few protections for children, some can be
exploited; but with too many obstacles, advances for them as a group will be slow.").
70. Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780 (codified in scattered
sections of 21 U.S.C.).
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for approval could simply submit adult studies demonstrating that their drug
was safe and effective for the claimed indication, and then rely on off-label
prescribing for all uses in other populations.7 ' In 1979, the FDA required
that pediatric labeling claims be supported by adequate pediatric tests, 72 but
this rule did nothing to change the system, which permitted approval of
drugs not tested in children so long as the labeling indicated the lack of
such testing. Such labels became known as "orphaning" clauses.73
While the FDA intended for this regulation to spur pediatric research, it
actually backfired. Sponsors decided it was more efficient to forgo the
pediatric tests and simply accept disclaimers on their labels.74 Therefore,
while the 1979 rule could guard children against false or unsubstantiated
claims, it resulted in another dangerous situation for pediatric patients-a
complete lack of any informative labeling.75 Unfortunately, this ineffective
and hazardous strategy remained the government's approach to protect
children until the 1990s. 76 In that decade, the emergence of HIV/AIDS as a
pediatric disease created a new sense of urgency with regard to pediatric
77
drugs and sparked both the FDA and Congress to make serious changes.
In 1990, the FDA began to incorporate into its review process the
"Pediatric Page," which is a form used for reviews of all new molecular
entities submitted for approval that details the adequacy of the label with
regard to pediatric information and any need, plans, or agreements between
the FDA and the sponsor for further studies in children.78 The FDA took
another step toward improvement in 1994 by allowing pharmaceutical
companies to use "adequate and well-controlled" adult studies, in addition
to pharmacokinetic, safety, and pharmacodynamic data, to support pediatric

71. Exploring the Frontiers,supra note 8, at 491, 493.
72. Labeling and Prescription Drug Advertising; Content and Format for Labeling for
Human Prescription Drugs, 44 Fed. Reg. 37,434 (June 26, 1979) (codified as amended in 21
C.F.R. pt. 201 and 202).
73. Breslow, supra note 7, at 151.
74. Id.
75. Id. at 148. This virtual abandonment of children is particularly ironic given that
several changes in the regulation of pharmaceuticals by the FDA have been sparked by
adverse events impacting children. For example, the 1906 Act resulted from the death of
several children from a diphtheria antitoxin infected with tetanus. The 1937 Amendments
came on the tails of the elixir of sulfanilamide disaster described supra note 18, and the 1962
Amendments stemmed from the Thalidomide-induced birth defects seen in Europe. Labson,
supra note 47, at 34-35.
76. Breslow, supra note 7, at 148.
77. Exploring the Frontiers,supra note 8, at 493.
78. Coming of Age, supra note 58, at 264. However, these forms are rarely completed in
any level of detail and often seem to be more of an afterthought in the approval process than
a substantive requirement because they simply summarize the state of pediatric studies at the
time an FDA action is taken on an application.
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labeling. 79 This rule did not actually require any new testing, but it did
require "all sponsors of drug and biologics products [to] examine available
data on pediatric use and submit a supplemental application for a pediatric
indication if supported by the existing data." 80 Nevertheless, manufacturers
could still opt for the disclaimer approach if the necessary information was
absent.8'
Despite good intentions, these FDA initiatives failed to achieve their
goals. As the FDA began to face increasing popular pressure on a number
of fronts in the late 1990s stemming from delayed access to new products,
increased competition from overseas, and disincentives for research due to
increased generic competition, it became clear that Congress needed to
intervene.8 2 This pressure finally led to a broad piece of responsive
legislation: the Food and Drug Administration Modernization Act of 1997
(FDAMA), 83 and the carrot-and-stick incentive/mandate system currently in
place.
B. FDAMA/Best Pharmaceuticalsfor ChildrenAct
The FDAMA established a pediatric studies incentive program in section
505A of the Federal Food, Drug, and Cosmetic Act.84 As a reward for
conducting pediatric trials specifically requested by the FDA, drug sponsors
holding approved applications and existing patents or other exclusivity were
offered a six-month extension of market exclusivity for all of their drug
products with the same active ingredient as the one studied.85 During this
six-month period, the FDA could not approve an abbreviated new drug
application for generics relying on the safety and efficacy data from the
original sponsor's new drug application (NDA).86 This legislation provided
a lucrative economic incentive for sponsors to perform the requested
research because they could delay generic competition.
79. Specific Requirements on Content and Format of Labeling for Human Prescription
Drugs; Revision of "Pediatric Use" Subsection in the Labeling, 59 Fed. Reg. 64,240 (Dec.
13, 1994) (codified as amended in 21 C.F.R. pt. 201).
80. Labson, supra note 47, at 40.
81. Breslow, supra note 7, at 152.
82. Coming ofAge, supra note 58, at 264-65.
83. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115,
111 Stat. 2296 (codified as amended in scattered sections of 21 U.S.C.).
84. See Federal Food, Drug, and Cosmetic Act § 505A,21 U.S.C.A. § 355a(b-c) (West
Supp. 2006).
85. Exploring the Frontiers,supra note 8, at 491 (explaining the incentive created by
this statute).
86. Coming of Age, supra note 58, at 265. However, generics could still be approved
during this six month period if they submitted their own research and did not rely on
materials from the pioneer's submission. Id.
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The process worked as follows: first, the FDA would issue a written
request that the sponsor outline the specific studies to be undertaken, the
study designs and goals, and the age groups to be tested.87 Studies had to
be completed and submitted as part of an NDA or supplemental NDA for
the new pediatric indication, but the application need not be approved to
qualify for exclusivity. 88 In other words, no labeling change had to occur so
long as the sponsor provided the FDA with information and data responsive
to the written request. 89 Finally, the FDA would negotiate with the sponsor
for the new indication or appropriate labeling revisions based on the
research. 90 Because the program was completely voluntary, sponsors who
received written requests could choose to conduct the studies based on their
own determination of whether the six-month exclusivity incentive justified
the costs of conducting the requested trials. This rewards structure made
the program the "carrot" in the current regulatory scheme for pediatric
research.
The pediatric exclusivity provision of the FDAMA included a sunset
provision and expired in 2002. However, due to its moderate success in
spurring pediatric testing and labeling changes, its basic premise and
incentives were reenacted, with some improvements, as the Best
Pharmaceuticals for Children Act (BPCA) that same year.9' Under the
BPCA, the FDA is authorized to make written requests for pediatric studies
based on the availability of information concerning the safe and effective
use of the drug in the pediatric population, whether new pediatric studies
concerning the drug will produce health benefits for children, and whether
reformulation of the drug for children is necessary.9 2
The BPCA still involves a voluntary system, but it establishes a twotiered approach to help ensure that important pediatric research is
performed even if sponsors do not take advantage of the statute's
incentive.9 3 If a sponsor responds to an FDA request, things then proceed
very similarly to how they would have under the FDAMA. However, a
sponsor's failure to respond triggers a new system. The BPCA establishes a
private foundation to support third party research on drugs still entitled to

87. Id.
88. Id.
89. Breslow, supra note 7, at 155.
90. Exploring the Frontiers,supra note 8, at 497.
91. Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, 115 Stat. 1408 (2002)
(codified as amended in scattered sections of U.S.C.). This statute has its own sunset clause
for 2007. Best Pharmaceuticals for Children Act, 21 U.S.C.A. §355a(n) (West Supp. 2006).
92. Best Pharmaceuticals for Children Act, 42 U.S.C.A. §284m (West Supp. 2006).
93. Breslow, supra note 7, at 134.
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patent protection or exclusivity. 94 This foundation issues contracts for the
requested studies, though in the case of insufficient foundation funding, the
drug can be included on a list for public contract research on off-patent/offexclusivity drugs. 95 If a sponsor rejects a written request because the drug
is ineligible for the incentive or if the drug was included on the list created
by the private foundation, the FDA will publish a request for a contractor to
conduct the research using public funds. 9 6 Between this two-tiered system
and a new provision that requires public dissemination of all studies
conducted under the FDA's written requests,97 the BPCA seems well poised
to improve the amount of information available to pediatric prescribers.
This goal is buttressed by the "stick" to the BPCA's "carrot"-the Pediatric
Research Equity Act (PREA).
C. PediatricResearch Equity Act
Passed in December of 2003, the PREA 98 codified the 1998 Pediatric
Rule promulgated by the FDA, which a federal district court struck down
for exceeding the FDA's authority. 99 This rule "empowered the FDA to
require pediatric testing of already marketed drugs and instituted a
presumption favoring pediatric testing and labeling for new drugs,"' 00 thus
creating a non-voluntary correlate to the FDAMA/BPCA pediatric
incentive. The PREA requires adequate data 0 1 to assess safety and efficacy
94. Public Health Services Act, 42 U.S.C. §290b (West Supp. 2002).
95. I. Glenn Cohen, Therapeutic Orphans, PediatricVictims? The Best Pharmaceuticals
for Children Act and Existing PediatricHuman Subject Protection, 58 FOOD & DRUG L.J.
661, 670 (2003).
96. See id. (describing this two-tiered system and the workings of the BPCA more
generally).
97. Best Pharmaceuticals for Children Act, 21 U.S.C.A. §355a(j) (West Supp. 2006).
All reports completed pursuant to the Act are part of the public domain and will be published
in the Federal Register. Breslow, supra note 7, at 175. Other improvements to the BPCA
include elimination of the user fee waiver for pediatric supplemental applications, the
creation of the Office of Pediatric Therapeutics to coordinate all FDA policy regarding
research in pediatric populations, and a requirement that the Institute of Medicine review
federal regulations governing pediatric research and submit a report including
recommendations on best practices relating to research involving children. Cohen, supra
note 95, at 670-71.
98. Pediatric Research Equality Act, Pub. L. No. 108-155 117 Stat. 1936 (2003)
(codified as amended in scattered sections of 21 U.S.C.).
99. Ass'n Am. Physicians & Surgeons, Inc. v. U.S Food and Drug Admin., 226
F.Supp.2d 204, 212 (D.D.C. 2002).
100. Breslow, supra note 7, at 160. The rule also allowed the FDA to punish
manufacturers for noncompliance by deeming an existing drug misbranded or a new drug
unlicensed. Id.
101. This data need not come exclusively from pediatric studies, but can also be
extrapolated from well-controlled adult studies when possible. Federal Food, Drug, and
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of a drug or biologic for the claimed indications of an NDA in all relevant
pediatric subpopulations, even if the sponsor has not specifically claimed
any pediatric uses. 10 2 The statute also requires data to support dosing and
administration for any 10
pediatric
subpopulations in which the drug is found
3
to be safe and effective.
The PREA is not all-inclusive and does recognize several waivers that
exempt NDAs from pediatric testing when sponsors make certain showings.
The requirements can be deferred if pediatric studies should be delayed
until additional safety or efficacy data have been collected in adult
subjects. 10 4 Additionally, where evidence strongly suggests the drug would
be ineffective or unsafe in all pediatric age groups, the requirements can be
waived entirely. 10 5 The requirements can also be waived if the drug does
not represent a meaningful therapeutic benefit over existing therapies for
pediatric patients
and is not likely to be used in a substantial number of
06
such patients.
The FDA can also require pediatric data for drugs already approved and
thus not covered by the requirements surrounding NDAs. This occurs if the
drug is used for a substantial number of pediatric patients for its labeled
indications, or if there is reason to believe the drug would represent
meaningful therapeutic benefit 1°7 over existing therapies for pediatric
patients.10 8 Both of these situations must be accompanied by a finding that

Cosmetic Act, § 505B, 21 U.S.C.A. § 355c(a)(2)(B)(i) (West Supp. 2006).
102. Federal Food, Drug, and Cosmetic Act § 505B 21 U.S.C.A. § 355c(a)(2)(A)(i)
(West Supp. 2006). This information must accompany applications for a new indication,
dosage form, route of administration, dosing regimen, or active ingredient. Federal Food,
Drug, and Cosmetic Act § 505B, 21 U.S.C.A. § 355c(a)(1)(A-B) (West Supp. 2006).
103. Federal Food, Drug, and Cosmetic Act § 505B, 21 U.S.C.A. § 355c(a)(2)(A)(ii)
(West Supp. 2006).
104. Federal Food, Drug, and Cosmetic Act § 505B, 21 U.S.C.A. § 355c(a)(3)(A)(i)
(West Supp. 2006).
105. Federal Food, Drug, and Cosmetic Act § 505B, 21 U.S.C.A. § 355c(a)(4)(A) (West
Supp. 2006).
106. Id. These deferral and waiver provisions provide an indirect comment on when
children's participation research is ethically justified in the eyes of the FDA. Rosato, supra
note 30, at 365.
107. Meaningful therapeutic benefit is defined in the Federal Food, Drug, and Cosmetic
Act as: "(1) if approved, the drug or biological product would represent a significant
improvement in the treatment, diagnosis, or prevention of a disease, compared with
marketed products adequately labeled for that use in the relevant pediatric population; or (2)
the drug or biological product is in a class of products or for an indication for which there is
a need for additional options." Federal Food, Drug, and Cosmetic Act § 505, 21 U.S.C.A. §
355c(c) (West Supp. 2006).
108. Federal Food, Drug, and Cosmetic Act § 505, 21 U.S.C.A. §355c(b)(1) (West
Supp. 2006). These requirements may also be waived in certain conditions. Federal Food,
Drug, and Cosmetic Act § 505, 21 U.S.C.A. §355c(b)(2) (West Supp. 2006).
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the absence of adequate labeling could pose significant risks to pediatric
patients.10 9
D. Impact of These Initiatives
With this carrot-and-stick approach, the regulation of pediatric research
may finally be on track to fill the informational void left by years without
industry incentive to conduct these studies. The tandem system has helped
to build the infrastructure for trials using child subjects, which occur far
more frequently now than ten years ago. 10 Between the passage of the
FDAMA in 1997 and the passage of PREA in 2003, the number of child
subjects nearly tripled"' as pharmaceutical companies began to "think
pediatric.""12 However, the question now is whether child subjects will be
adequately protected in this new environment,'" 3 a question that will be
asked specifically with regard to studies requested by the FDA under the
BPCA and will serve as the focal point for the remainder of this article.
PART IV-ARE THE REQUESTED PLACEBO-CONTROLLED PEDIATRIC
STUDIES APPROVABLE UNDER THE FEDERAL REGULATIONS?

Under its authority from the BPCA, the FDA has created templates to
drugs used to treatl5
serve as written request models for pediatric studies 1of
14
and depression"
depression, OCD, HIV, and cancer. The OCD
templates both specifically request placebo-controlled trials, while the

109. Federal Food, Drug, and Cosmetic Act § 505, 21 U.S.C.A. §355c(b)(1) (West
Supp. 2006).
110. Meadows, supra note 20, at 13-14.
111. VERA HASSNER SHARAV, ET AL., THE ALLIANCE FOR HUMAN RESEARCH
PROTECTION, COMMENTS TO THE NATIONAL ACADEMY OF SCIENCES COMMITTEE OF THE
INSTITUTE OF MEDICINE ON CLINICAL RESEARCH INVOLVING CHILDREN (Aug. 18, 2003),

http://www.ahrp.org/testimonypresentations/BestPharmaAct0803.php (last visited Sept. 22,
2006)
112. Exploring the Frontiers,supra note 8, at 496.
113. E.g., Flynn, supra note 20, at 868 ("[I]t is incumbent on researchers to develop
research procedures that will not only answer the scientific questions of interest but also
protect this vulnerable patient population from harm."); SHARAV, supra note I11
("Unfortunately, the law failed to balance financial incentives with new (or improved)
safeguards to protect an increased number of young children who are being exposed to the
hazards of research. As a result, children who are legally precluded from exercising the right
to refuse are being aggressively recruited to bear the burden of testing drugs that may (or
may not) be safe or in their best interest.").
114. FDA, OCD Template, http://www.fda.gov/cder/pediatric/OCD-wr-template.htm
(last visited Sept. 29, 2006).
Template,
http://www.fda.gov/cder/pediatric/
115. FDA,
Antidepressant
antidepressant wr template.htm (last visited Sept. 29, 2006).
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HIV 1 6 and oncology1 17 drug study requests are far more open-ended
regarding trial design and do not require placebo controls. Before asking
whether the use of placebos to test these drugs in children is ethically
acceptable, this article will first explore whether that issue is moot through
a legal analysis of whether these studies are even approvable under an
appropriate application of the federal regulations governing the conduct of
pediatric research.
A. History of Regulations GoverningPediatricResearch
The development of research ethics did not begin in earnest until the
middle of the twentieth century. Following World War II and the
Holocaust, the Nuremberg Code" 8 forbade research using non-consenting
subjects, which effectively, although not explicitly, prohibited all research
Given the
on children because of their incapacity to consent.11 9
demonstrated need for pediatric research and due to its wide recognition as
overly restrictive, 20 the Nuremberg Code was displaced on the international
stage in 1964 by the World Medical Association's Declaration of
Helsinki. 121 This declaration directly responded to the Nuremberg Code's
shortcomings by permitting surrogate consent for nontherapeutic research
on those legally unable to provide consent themselves, such as children and
the mentally disabled. 22 Though certainly important, these international
codes simply served as guidelines lacking the force of law and the ability to
bind researchers, highlighting the need for government intervention in this
area. By the late 1960s and early 1970s, several exposes of unethical

116. FDA, HIV Template, http://www.fda.gov/cder/pediatriciHIV2-template.htm (last
visited Sept. 29, 2006).
117. FDA,
Oncology
Template,
http://www.fda.gov/cder/pediatric/
oncologytemplate.htm (last visited Sept. 29, 2006). This template is far less detailed than the
others, probably because there are so many different types of cancer that a more general
template would not have been feasible. Id.
118.

2 TRIALS OF WAR CRIMINALS BEFORE THE NUERNBERG MILITARY TRIBUNALS UNDER

CONTROL COUNCIL LAW No. 10 181-82 (U.S. Gov't Printing Office, Oct. 1946 - Apr. 1949),

availableat http://ohsr.od.nih.gov/guidelines/nuremberg.html.
119. Loretta M. Kopelman, What Conditions Justi. Risky Nontherapeutic or "No
Benefit" Pediatric Studies: A Sliding Scale Analysis, 32 J.L. MED. & ETHICS. 749, 749
(2004) [hereinafter Sliding Scale].
120. Rupali Gandhi, Research Involving Children: Regulations, Review Boards and
Reform, 8 J. HEALTH CARE L. & POL'Y 264, 268 (2005) (noting that Nuremberg's strict
prohibition would be harmful because it would prevent medicine from advancing in the
treatment of childhood diseases).
121.
WORLD MED. ASS'N, DECLARATION OF HELSINKI (1964), http://www.wma.net/
e/policy/pdf/17c.pdf.
122. INST. OF MED., supra note 18, at 49-50.
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policy-makers to
research on vulnerable populations forced American
123
confront the lack of ethical guidelines in research.
Finally, in 1973, the Department of Health, Education, and Welfare (now
the Department of Health and Human Services (HHS)) issued a working
document on experimentation with children that proposed several specific
protections.1 24 Though HHS failed to publish final rules governing the
conduct of clinical research until almost a decade later, these rules, codified
at 45 C.F.R. § 46, were based on the report of the National Commission for
the Protection of Human Subjects of Biomedical and Behavioral Research
and include special protections for certain groups, such as children,
pregnant women, and prisoners. These regulations initially covered only
studies funded by HHS and did not apply to privately conducted research
submitted to the FDA to support the approval of various drug
applications.1 25 Fortunately, after nearly twenty years of this differential
treatment, Congress enacted the Children's Health Act of 2000, which
required that all research involving children conducted, supported, or
regulatedby HHS be in compliance with the existing pediatric rules, widely
D, 126 thus extending these rules to all studies submitted to
known as 12Subpart
7
the FDA.

B. The FederalRisk Categories
The FDA, like its umbrella agency HHS, uses a system of risk categories
to guide IRBs faced with the decision of whether to approve proposed
123. Id. at 50. Several research scandals were highlighted in Henry K. Beecher's
influential article describing twenty-two problematic studies in which consent was never
obtained from subjects. Ethics and Clinical Research, 274 NEW ENG. J. MED. 1354, 135559 (1966). In addition, the Tuskegee study was exposed in 1972, probably the most
important research scandal to ever occur in the United States and one of the major driving
forces finally sparking federal intervention into the medical research arena. This study was
intended to observe the natural course of syphilis in untreated African-American patients.
When it began, there was no effective treatment, but even after penicillin became widely
available as the standard of care, patients were denied treatment, and even deceived into
avoiding appropriate medication. Beauchamp & Faden, supra note 29, at 1275.
124. INST. OF MED., supra note 18, at 51.
125. Breslow, supra note 7, at 138-39.
126. Children's Health Act of 2000, Pub. L. No. 106-310, 114 Stat. 1167.
127. FDA did not adopt the existing HHS regulations wholesale, but made minor
changes based on its particular responsibilities and functions, consciously trying to keep
things as uniform as possible so as to reduce regulatory burden on institutions and IRBs.
Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products,
66 FED. REG. 20,589, 20,591 (Apr. 24, 2001) (codified at 21 C.F.R. pt. 50, 56) [hereinafter
Additional Safeguards]. In its Interim Rule following the Children's Health Act, the FDA
stated that it was requiring additional safeguards to protect children because of expected
increases in the enrollment of children in clinical investigations as a result of recent pediatric
initiatives, at that time, the FDAMA and the 1998 Pediatric Rule. Id. at 20,589.
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pediatric research.12 8 This system requires the board to balance the risks
and benefits to the child posed by the research, the potential benefit to
children as a group, and the individual child's ability to assent. 29 Based on
these considerations, the research must fall into one of four categories of
approvable research or it cannot proceed. 130 The risk categories essentially
create a sliding scale, so that "[t]he more the research project resembles
standard medical care, the less it is regulated. The closer it comes to pure
research, in which the creation of new knowledge is the sole or primary
' 31
goal, the more it is regulated."'
Importantly, the risk categories established in Subpart D apply to each
individual intervention included in a study protocol and not to the study as a
whole, such that the placebo and experimental arms of a study could
potentially be categorized differently. 132 If the entire study was viewed
together, the benefit from one component could justify the risks of the other
components.
However, under the regulations, IRBs must separately
analyze risks for each procedure involved in the protocol. 133 These federal
regulations nonetheless fail to deal specifically with the use of placebo
controls in pediatric research, 134 leaving researchers without clear guidance
on how the FDA's requests for pediatric OCD and depression studies
should be classified and whether they are approvable at all.

128. "In addition to other responsibilities assigned to IRBs under this part and part 56 of
this chapter, each IRB must review clinical investigations involving children as subjects
covered by this subpart D and approve only those clinical investigations that satisfy the
criteria described in 50.51 [minimal risk], 50.52 [greater than minimal risk and direct
benefit], or 50.53 [greater than minimal risk and no direct benefit] and the conditions of all
other applicable sections of this subpart D." 21 C.F.R. § 50.50 (2006). This part of the
regulation lists only three risk categories because the fourth is a catchall that cannot be
approved by an IRB, but needs approval by the Commissioner of Food and Drugs, after
consultation with a panel of experts in pertinent disciplines, following opportunity for public
review and comment. 21 C.F.R. § 50.54 (2006).
129. William J. Wenner, Does the Legal System Provide Adequate Protection for
Children in Scientific Experiments? The Unanswered Question of Grimes v. Kennedy
Krieger Institute, 8 U.C. DAVIS J. Juv. L. & POL'Y 243, 258 (2004).
130. 21 C.F.R. § 50.50. These risk categories and their related requirements are
endorsed, adopted, and agreed with by the American Academy of Pediatrics. Am. Acad. of
Pediatrics, supranote 4, at 288.
131. Glantz, supra note 40, at 232.
132. Gandhi, supra note 120, at 280. See also Franklin G. Miller et al., When Do the
Federal Regulations Allow Placebo-Controlled Trials in Children?, 142(2) J. PEDIATRICS
102, 103-04 (2003) (pointing out that reviewers cannot justify a risky procedure just because
something else in the protocol would have a benefit because that sort of analysis exemplifies
the "fallacy of the package deal").
133. Gandhi, supra note 120, at 280.
134. Rosato, supra note 30, at 366.
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1. Minimal Risk (21 C.F.R. § 50.51)
The first category under which pediatric research is approvable is not
very controversial because it involves an insignificant chance of harm to
child subjects. The regulation provides that
[a]ny clinical investigation ...in which no greater than minimal risk to
children is presented may involve children as subjects ... if the IRB finds

and documents that adequate provisions are made for soliciting the assent
135
of the children and the permission of their parents or guardians ....
Such research need not present direct benefit to the subjects because the risk
to the child is minimal. That is, "the probability and magnitude of harm or
discomfort anticipated in the research are not greater in and of themselves
than those ordinarily encountered in daily life or during the performance of
routine physical or psychological examinations or tests. ' 136 However, this
definition leaves open the important question of whose daily life should
serve as the comparator.
A technical or literal reading of the language in this modestly regulated
risk category could permit research posing substantial risk to children
because the risks of daily life vary based on age, health status, social strata,
and geographic location. 137 If minimal risk is truly tied to such subjective
variables, researchers could conduct riskier research on children already
disadvantaged by the risky situations they face in their own lives, raising
concern about the unjust distribution of research burdens. 138 For this
reason, a more objective definition of minimal risk is almost universally
used in place of the unacceptable relativistic theory of minimal risk.
Ethicists and responsible IRBs generally understand minimal risk to refer to
the daily life of the average healthy child, as opposed to those risks facing
the particular subject in his or her particular life. 13 9
135. 21 C.F.R. § 50.51 (2006). The permission of one parent may suffice for this type
of research. 21 C.F.R. § 50.55(e)(1) (2006). Examples of procedures that the FDA
considers to fall into this category include "clean-catch urinalysis, obtaining stool samples,
administering electroencephalograms, requiring minimal changes in diet or routine, the use
of standard physiological tests," and taste tests or temperature readings orally or in the ear.
Additional Safeguards, supra note 127, at 20,593. None of these examples describe protocol
options, such as the use of placebo controls or other study designs, and they fail to provide
potentially more helpful examples of what sorts of procedures would not be minimal risk.
136. 21 C.F.R. § 50.3(k) (2006).
137. Cohen, supra note 95, at 689-90. See also Glantz, supra note 40, at 233 (exploring
this problem).
138. Cohen, supra note 95, at 690.
139. This objective interpretation has been supported by the National Human Research
Protections Advisory Committee, Gandhi, supra note 120, at 282, the Institute of Medicine,
INST. OF MED., supra note 18, at 122, the Office of Protection from Research Risks, and
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Nevertheless, some commentators rely on the current dearth of
information on pediatric prescriptions to conclude, controversially, that
many pediatric trials could be categorized as minimal risk even under this
objective definition. They reason that "[w]hen there is no known effective
treatment for the condition under study, the use of placebo poses minimal
risks to children." 140 This is because

[t]he category of "no known effective treatment" includes both no
treatment and a treatment whose safety and efficacy have not been
established. In these cases, children who receive placebo in research are
receiving essentially the same thing they would receive outside of the
research context, namely, no effective treatment for their condition. 141
Moreover, minimal risk has been described as the "socially permissible
level of risk that parents would normally permit their children to be exposed
to in non-research settings."'142 As discussed in Part I.A., as many as eighty
percent of drugs currently on the market pose some risk of adverse events
or ineffectiveness when prescribed to children due to inadequate labeling
143
for pediatric use and deficiency of information about safety and efficacy.
Therefore, placebo control arms seem to meet the requirements of this risk
category because the risk of receiving ineffective treatment is the same as
that encountered by the average child during the course of ordinary clinical
practice.
While this reasoning could theoretically extend to the placebo-controlled
studies requested by the FDA for pediatric OCD and depression, the
severity of these conditions gives reason for pause. Unlike otherwise
healthy children who only need medication for routine ear infections or
twenty-four hour "bugs," children suffering from OCD and depression are
neither average nor healthy. These children face more than minimal risk
because the probability and magnitude of harm or discomfort anticipated
from placebo, no treatment, or ineffective treatment are greater than those
ordinarily encountered in the daily lives of average healthy children. Thus,
it is not the use of placebos that place these FDA requests outside of the
President Clinton's National Bioethics Advisory Commission, Group Benefit, supra note 69,
at 184. There is additional support for the objective approach based on 21 C.F.R. § 50.53,
permitting research that poses only a minor increase over minimal risk, keyed to the specific
lives of the subjects themselves. 21 C.F.R. § 50.53 (2006). The relativistic interpretation
would render § 50.53 virtually meaningless because then minimal risk and minor increase
over minimal risk would refer to the same thing: this objective approach best preserves the
independent value of each section.
140. Miller et al., supra note 132, at 104.
141. Id. at 104-05.
142. Gandhi, supra note 120, at281.
143. Am. Acad. of Pediatrics, supra note 4, at 286.
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minimal risk category, but rather the conditions themselves for which
research is needed that prevent both the experimental and control arms of
the FDA's requests from being approvable under 21 C.F.R. § 50.51.
2. Therapeutic Research (21 C.F.R. § 50.52)
The placebo-controlled trials requested by the FDA for OCD and
depression fare better under the therapeutic research risk category, but not
for long. Unlike minimal risk, this category is defined by the level of
potential benefit the intervention offers to participants, which can offset
more risk than is normally experienced in the daily lives of average healthy
children. 144 The regulation provides that:
Any clinical investigation . . . in which more than minimal risk to

children is presented by an intervention or procedure that holds out the
prospect of direct benefit for the individual subject . . . may involve

children as subjects only if the IRB finds and documents that: (a) The risk
is justified by the anticipated benefit to the subjects; (b) The relation of
the anticipated benefit to the risk is at least as favorable to the subjects as
that presented by available alternative approaches; and (c) Adequate
provisions are made for soliciting the assent of the children and
permission of their parents or guardians .... 145
Importantly, the presence of a direct benefit does not end the inquiry. The
IRB must consider whether that benefit is of sufficient magnitude to
outweigh the likelihood of any risks associated with the research.
Additionally, the requirement that the anticipated risk-benefit ratio of the
intervention mirror that of available alternatives seems to mandate a
determination of clinical equipoise.146 If neither arm of the study is known
to be better or worse, and the same is true for all available alternatives to
those arms, then equipoise exists and the study meets the "at least as
favorable" requirement of the regulation. 147 Although research approved
under this category can be quite risky, section 50.52 causes little
controversy because child subjects stand to gain direct benefit from their

144.

21 C.F.R. § 50.52 (2006).

145. Id. Each of the federal risk categories demands that adequate provisions are made
for soliciting the assent of the child subjects and the permission of their parents as an
approval criterion. Under §§ 50.51 and 50.52, the permission of only one parent is
sufficient, if consistent with state law, but both parents must give permission for research
approved under §§ 50.53 and 50.54, unless only one parent has full legal responsibility for
the child. 21 C.F.R. § 50.55(e). The more important difference in each category lies in the
level of risk permitted.
146. Fisher & Keens, supra note 19, at 843.
147. Id. For a more detailed discussion of clinical equipoise, see infra Part V.A. 1.
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participation. 48 However, things can become more complex depending on
the definition of "direct benefit."
149
"Hold[ing] out the prospect of direct benefit for the individual subject"
is both broad and vague, and, despite its centrality to the therapeutic
research risk category, federal regulations fail to define this phrase.
"Benefit" could be defined to include the entire range of research "perks,"
such as payment, physical examinations, increased medical attention over
what a subject would normally receive (or could afford) in clinical care, or
even the psychological benefit of doing something good for others. While
an IRB might interpret direct benefit this expansively, a narrow definition is
necessary to avoid characterizing all research as therapeutic.
In 1999, the FDA's Pediatric Advisory Subcommittee issued a consensus
statement classifying altruism or other psychological benefits as insufficient
to qualify research for approval under this risk category. 150 Nonetheless,
the statement is still overly broad because it includes benefit to the general
population of children as conferring direct benefit to the subjects
themselves. 151 The consensus statement explains that if the affliction under
study is one likely to affect a large proportion of the pediatric population,
such as a routine ear infection, research could fall under this risk
category. 152 It will do so even if the individual subjects are not presently
afflicted because they are likely to suffer from the problem at some point
1 53
and direct benefit would accrue to them at that time.
This definition focuses on the "holding out" language of the regulation,
allowing future benefit to satisfy the direct benefit requirement. While this
understanding does technically fit the regulation, it is more appropriate to
assume that this risk category requires the direct benefit to occur during the
subject's enrollment period. This interpretation best protects child subjects
as a group and helps ensure the meaningfulness of the direct benefit
requirement. Because the very point of clinical research is to benefit future

148. 21 C.F.R. § 50.52. Some commentators, however, consider it inappropriate to label
any research as therapeutic because it risks propagation of the misconception that research
will focus on the individual well-being of the subject when the real goal of research is
generalizable knowledge that will help not necessarily the research patient, but future
patients. Fisher & Keens, supra note 19,. at 825. This category seems to mask the fact that
the very point of research is based on the fact that investigators are unsure whether the
intervention will offer any benefit at all, let alone its adverse effects. Id. at 824.
149. 21 C.F.R. § 50.52.
150. FDA, FDA Ethics Working Group Consensus Statement on the Pediatric Advisory
Subcommittee's November 15, 1999 Meeting, http://www.fda.gov/cder/pediatric/ethicsstatement.htm [hereinafter Consensus Statement].
151. Id.; Rosato, supra note 30, at 366-67.
152. Consensus Statement, supra note 150.
153. Rosato, supra note 30, at 366.
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patients, this requirement could be too easily satisfied if all researchers
must demonstrate is some chance of future benefit to the individual
subjects. Furthermore, the heavy focus of the consensus statement on
benefit to the general population comes at the expense of the individual
subject who may never suffer from the affliction. 154 The fact that the
regulation discusses only the prospect of direct benefit demonstrates that
this category does not require an actual guarantee of direct benefit to
subjects. However, consideration of the general population edges towards
the nontherapeutic risk category, discussed below, suggesting that the
definition of direct benefit must be further narrowed in order for each
section of the regulations to have independent meaning.
So far, this article has established that the direct benefit to child subjects
required by section 50.52 cannot simply be the psychological benefit
associated with helping others and that the benefit should accrue to
individual child subjects during the course of their participation in the
study. But can benefits from the placebo effect or increased medical
attention from investigators suffice? The FDA has explicitly recognized the
ambiguity that the direct benefit requirement poses. In the 2001 Interim
Rule, in which it adopted Subpart D following the Children's Health Act,
the FDA stated that "clinical investigations involving placebos in children
may be conducted in accord with Sec. 50.52. There is evidence of direct
benefit to subjects from participating in placebo-controlled trials, including
increased monitoring and care of' 55subjects even though a subject may not
actually receive the test product."'
This explanation appropriately recognizes that risks associated with a
placebo control arm cannot be justified based on the benefits of the
experimental arm and that the placebo group must have its own direct
benefits. Importantly, under this formulation both the experimental and
control arms of the requested studies for pediatric OCD and depression
drugs would likely satisfy the direct benefit requirement, and thus fall under
the relatively nonrestrictive therapeutic category of Subpart D. However,
the FDA's statement is not normatively appropriate because the "benefits"
listed are still too broad.
Assessment of a research procedure's potential benefits should not
include consideration of unrelated collateral, indirect, or side benefits not
related to the research objectives.156 In other words, direct benefits should
include only those benefits actually intended by the research hypotheses.' 5 7
154.
155.
156.
157.

See Group Benefit, supra note 69, at 186.
Additional Safeguards, supra note 127, at 20, 593.
INST. OF MED., supra note 18, at 132.
See Cohen, supra note 95, at 679 (explaining direct benefit as that expected if the
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For example, the hypothesis of one of the FDA's requested studies would
be that an antidepressant that works well in adults, but is unproven in
children, would also work well in children. Subjects who receive this
antidepressant stand to gain a direct benefit because if that hypothesis is
correct, their depression will improve. The hypothesis intends no benefit to
the placebo group and if there is any benefit, either through the placebo
effect158 or increased medical attention, it is purely incidental. Therefore,
the best definition of "direct benefit" would require that the benefit at least
be intended as the very reason that the research was undertaken. This
definition allows for the experimental arms of pediatric research to be
categorized as therapeutic, but prevents placebo controls from ever meeting
the direct benefit standard, despite the FDA's own statement to the
contrary. 159 Adopting this definition does not mean that placebo controls
could never be approved for use in child subjects, but rather that their use is
more appropriately categorized as nontherapeutic research subject to more
stringent requirements and stricter subject protections.
Clearly, the FDA has the authority to reasonably interpret its own
regulations, and IRBs could permissibly evaluate both the experimental and
control arms of the OCD and depression studies requested under the BPCA
according to the requirements of the therapeutic risk category. However,
under the most normatively appropriate definition of "direct benefit," which
requires an intentional benefit that accrues to individual child subjects
during their participation, a placebo-control arm cannot meet this standard.
Therefore, the next subsection of this article will analyze the approvability
of the FDA's requests under the nontherapeutic risk category. The section
will also explain why this use of placebos will soon be non-approvable
under any risk category, even assuming that the FDA's definition of direct
benefit is appropriate.

hypothesis of the research is correct).
158. The placebo effect may actually provide significant benefit to a subject. In fact,
some commentators note that between 35% and 75% of research subjects derive some
benefit from taking inactive agents alone. Sharona Hoffman, The Use of Placebos in
Clinical Trials: Responsible Research or Unethical Practice?, 33 CONN. L. REv. 449, 45556 (2001).
159. See, e.g., Jack Schwartz, Research and Children'sHealth: The Court of Appeals as
Bioethics Commission, 36 MD. B.J. 8, 10 (Jan./Feb. 2003) (stating that the placebo arm is
something that would be considered nontherapeutic); and Benjamin Wilfond, Ethical Issues
in PediatricResearch: Placebo Controlled Trials for GastroesophagealReflux, June 25,
2002, http://www.fda.gov/ohrms/dockets/ac/02/slides/3870S1 04_Wilfond/ (noting that the
placebo arm does not offer the prospect of direct benefit).
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3. Nontherapeutic Research (21 C.F.R. § 50.53)
As compared to sections 50.51 and 50.52, the nontherapeutic research
category found in 21 C.F.R. § 50.53 is far more controversial among
ethicists because of its inherently utilitarian nature. 60 In a structure similar
to the previous two, the regulation provides that:
Any clinical investigation . . . in which more than minimal risk to
children is presented by an intervention or procedure that does not hold
out the prospect of direct benefit to the individual subject . . . may
involve children as subjects only if the IRB finds and documents that: (a)
The risk represents a minor increase over minimal risk; (b) The
intervention or procedure presents experiences to subjects that are
reasonably commensurate with those inherent in their actual or expected
medical, dental, psychological, social, or educational situations; (c) The
intervention or procedure is likely to yield generalizable knowledge about
the subjects' disorder or condition that is of vital importance for the
understanding or amelioration of the subjects' disorder or condition; and
(d) Adequate provisions are made for soliciting the assent of the children
and permission of their parents or guardians .... 161

The utilitarian "problem" arises due to the fact that child subjects are
exposed to more risk than would be experienced by an average, healthy
child, but that risk is compensated only by benefit to children generally and
not to the individual subject.
In other words, child participants in this category of research are asked to
undertake risks solely for the benefit of others. While adults are routinely
permitted and asked to do this, it may be problematic for children who are
not yet legally or developmentally able to consent to such self-sacrifice.
Some ethicists are opposed to nontherapeutic research in children for this
important reason.1 62 Though it may be less than ideal, and unacceptable to
160.

See JOHN STUART MILL, UTILITARIANISM 22-23 (Oskar Piest ed., Bobbs-Merrill Co,

Inc, 1957) (1861). Utilitarianism is a moral philosophy that considers ethical actions to be
those that produce the greatest good for the greatest number of people, permitting the
sacrifice of some for the benefit of others. Id. The comparisons to the context of human
subjects research are obvious, but some research is more clearly utilitarian than others,
especially those trials that intend no direct benefit to research participants but are hoping for
scientific breakthroughs for the benefit of society more generally.
161. 21 C.F.R. § 50.53.
162. Ramsey, supra note 12, at 11. (stating that "children who cannot give a mature and
informed consent ...should not be made the subjects of medical experimentation unless,
other remedies having failed to relieve their grave illness..."). For an important discussion
of the consent issue in more detail, see Part V.C infra. Importantly, however, Ramsey's
approach would prevent much needed research to obtain information about pediatric
prescribing.
The American Academy of Pediatrics recognizes the need to avoid
abandonment of pediatric research necessary for the benefit of children as a class and thus
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a strict deontologist, 163 the utilitarian category is extraordinarily important
because it remains unclear whether necessary information about the use of
pharmaceuticals in pediatric patients could be gleaned through therapeutic
research alone. 64 In fact, "[t]he openness of the federal regulations to
nontherapeutic pediatric research suggests the viewpoint that
nontherapeutic research, despite its ethical difficulties, may sometimes be
critical to the advancement of important knowledge.' 6 5 Further, the sort of
research approvable under this nontherapeutic category exposes subjects
only to the levels of risk that are standard for their conditions, helping to
justify the lack of benefit they can personally expect as a result of their
participation.
Section 50.53 permits research that poses only a minor increase over
minimal risk; however, it fails to clearly define that phrase, leaving it
generally to the discretion of IRBs. 166 Recall that minimal risk is keyed to
the amount of risk experienced in the daily lives of average healthy
children.' 67 In contrast, this nontherapeutic category does not use the
average healthy child as a reference point, but rather focuses on the
subjective risks faced in the daily lives of the research subjects themselves.
Thus, if a pediatric cancer patient experiences spinal taps on a weekly basis,
then spinal taps and other experiences with similar pain and risk levels
would be permitted in a research study under this category, even though the
permits studies that either have a potential benefit to the individual child (i.e. § 50.52) or
provide generalizable knowledge (i.e. § 50.53) when potential benefits outweigh potential
risks. Am. Acad. of Pediatrics, supranote 4, at 288.
163. Deontologists are characterized by a belief that individuals should never be used
merely as means, but always treated as ends in themselves. Because the research enterprise is
focused almost exclusively on obtaining generalizable knowledge and not on individual
treatment and benefit for the subject, it has a utilitarian slant, but when individual benefit is a
requirement, as under § 50.52, the subject is not treated as a mere means, and thus, the
research is justifiable even under deontological theory. For a foundation of deontological
philosophy, see IMMANUEL KANT, GROUNDWORK OF THE METAPHYSIC OF MORALS (H.J.
Patton trans., Harper & Rowe 1964); IMMANUEL KANT, CRITIQUE OF PRACTICAL REASON
(Lewis White Beck trans., Liberal Arts Press 1956); and IMMANUEL KANT METAPHYSICS OF
MORALS (Mary Gregor trans., ed., Cambridge University Press 1996).
164. See Sliding Scale, supra note 119, at 754 (discussing the utilitarian nature of the
risk categories utilized by Subpart D). See also Lainie Friedman Ross, Children As
Research Subjects: A Proposal to Revise the Current Federal Regulations Using a Moral
Framework, 8 STAN. L. & POL'Y REV. 159, 166 (1997) (addressing the particularly
problematic nature of 21 C.F.R. § 50.54 that permits great risks for child subjects for the
benefit of society).
165. Smolin, supra note 3, at 631. However, the FDA will not accept information
submitted for pediatric exclusivity if that data is derived from children who do not suffer
from the condition under study and for whom there is no foreseeable benefit. SHARAV, ET
AL., supra note 111.
166. See 21 C.F.R. § 50.53.
167. See supra Part IV.B.1.
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risks go beyond what an average healthy child routinely experiences.
"[M]inor increase over minimal risk" can therefore be thought of as the
equivalent of minimal risk specifically68keyed to that group of children with
the disorder or condition under study. 1
The definition of "condition" within the regulation has also sparked
significant debate because a broad definition of the term could cover even
the simple "condition" of being a child, allowing all pediatric research to
satisfy that criterion. Nonetheless, OCD and depression clearly fit the more
narrow definition of condition as "a specific (or set of specific) physical,
psychological, neurodevelopmental, or social characteristic(s) that an
established body of scientific evidence or clinical knowledge has shown to
negatively affect children's health or well-being or to increase their risk of
developing a health problem in the future."'1 69 Therefore, the placebo
control arms of the studies requested by the FDA of drugs to treat OCD and
depression in children easily satisfy the section 50.53 requirement that the
intervention be likely to yield generalizable knowledge about OCD and
depression because they will be used to gauge whether the response to the
experimental intervention is statistically significant. The knowledge gained
is also vital to the understanding and amelioration of these prevalent
pediatric conditions, given the dearth of existing information on how to
treat pediatric OCD and depression that prompted the FDA to request these
studies in the first place. 170 Assuming that researchers can adequately
obtain assent and permission, taking a placebo and being closely monitored
by researchers will present experiences that are reasonably commensurate
with what the child subjects would experience in their normal clinical
encounters. Therefore, when questioning whether placebo controls are
168. Group Benefit, supra note 69, at 189. Some commentators have argued that this
definition suffers from the same ethical problem that was cause for rejection of the
subjective definition under the minimal risk category because it permits researchers to
impose more risk on sicker children even without the prospect of direct benefit-if one
spinal tap is risky, then two are riskier, and that risk should be compensated by direct
benefit. See Glantz, supra note 40, at 233.
169. INST. OF MED., supra note 18, at 6. If "condition" is understood as only a fully
expressed disease or disability, it would be much more difficult to do pediatric research that
is of more than minimal risk because the scope of possible subjects would be significantly
narrowed. See Sliding Scale, supra note 119, at 751. In reality, the boundaries between
being healthy, at risk, and having a disease are blurry, so if the definition of condition is
broader, more children can be subjected to greater than minimal risk research of their
"conditions." See id. However, if the term is interpreted too broadly so as to include
anything associated with illness, such as race, ethnicity, age, environment, social and
economic circumstances, and the like, then almost anything, including the mere fact of being
a child, could be approved under this risk category and the condition requirement would no
longer pose a real barrier, id. at 751-52, allowing the research on healthy children that this
category was intended to exclude. Cohen, supra note 95, at 702.
170. Miller et al., supra note 132, at 106.
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approvable under the nontherapeutic risk category, the only real issue is
whether they pose no more than a minor increase over minimal risk.
Minor increase over minimal risk occurs when subjects are simply
exposed to the same level of risk that they would face in their own lives,
even if that is more risk than what the average, healthy child would face.
When a pediatric subject is denied treatment of questionable safety or
efficacy when no proven alternative exists, the use of placebo controls will
likely satisfy the minor increase over minimal risk criterion because
subjects receiving placebo would not receive anything better for their
condition in ordinary clinical care. Because no treatments have been
proven safe since the recent pediatric sucidality concerns associated with
drugs used or approved to treat OCD and depression in children, this
precisely describes the present situation.
Prozac is the only drug currently approved and labeled for pediatric
depression, and no other antidepressants have proven more effective than
placebo in pediatric subjects.' 71 Despite this singular approval, all
antidepressants, including Prozac, have recently been required to include a
"black box" warning describing "the increased risk of suicidality in children
and adolescents given antidepressant medications ....
These labeling
changes are applicable to the entire category of antidepressant medications
because the currently available data are not adequate
to exclude any single
172
medication from the increased risk of suicidality."'
Concerns regarding antidepressant drugs in children are not limited to
their use for pediatric depression, but also extend to their use for treating
pediatric OCD, 173 including the handful of antidepressant medications
171. FDA, Questions and Answers on Paxil (paraxetine hydrochloride), June 19, 2003,
http://www.fda.gov/cder/drug/infopage/paxil/paxilQ&A.htm
(stating
that
"Prozac
(fluoxetine) is the only drug approved for the treatment of major depressive disorder in
children... 8 to 18 years of age."). Prozac was approved for this indication in children ages
8-18 following studies requested under the BPCA. FDA, Pediatric Program Study Statistics
1,
http://www.fda.gov/ohrms/dockets/ac/04/briefing/4006B 04 Ped%20ExclusivityOCD wr template.doc (last visited Sept. 25, 2006). Efficacy was established in this
population "based on two placebo controlled clinical trials in depressed outpatients whose
diagnoses corresponded to standard rating criteria (under the American Psychiatric
Association's Diagnostic and Statistical Manual). . . The studies of Prozac for depression
produced a statistically significant effect for the drug compared to placebo on the 'Childhood
Depression Rating Scale R (revised)."' FDA, FDA Talk Paper: FDA Approves Prozac for
Pediatric Use to Treat Depression and OCD, Jan. 3, 2003, http://www.fda.gov/bbs/
topics/ANSWERS/2003/ANS0 1187.html.
172. Press Release, FDA Launches a Multi-Pronged Strategy to Strengthen Safeguards
for Children Treated With Antidepressant Medications (Oct. 15, 2004), http://www.fda.gov/
bbs/topics/news/2004/NEW 01124.html.
173. FDA, Class Suicidality Labeling Language for Antidepressants, Jan. 26, 2005,
http://www.fda.gov/CDER/DRUG/antidepressants/PItemplate.pdf ("The risk of suicidality
was most consistently observed in the MDD [Major Depressive Disorder] trials, but there
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approved with specific indications for that condition: Prozac, Zoloft, Luvox,
and Anafranil. 74 While effective drugs exist to treat both OCD and
depression in pediatric patients, the fact that all available treatments are of
questionable safety permits placebo controls to be categorized as only a
minor increase over minimal risk. The risk facing those subjects
randomized to receive placebo mirrors the risk that those particular subjects
would face in their everyday lives, namely the lack of appropriate treatment
for their condition, which satisfies the final criterion for approval under
section 50.53.175
However, this situation will change as soon as even a single drug for
OCD and/or depression overcomes the existing suicidality concerns. Once
there is a safe and effective alternative treatment for either of these
conditions, denial of that treatment in favor of placebo would pose more
than a minor increase over minimal risk because the placebo group would
be exposed to the risk of non-treatment.1 76 However, now that risk would
be greater than what the subjects would face in their daily lives because
they would receive safe and effective treatment as the standard of care if
they were not part of the study. If a minor increase over minimal risk is
defined as the subjective version (average risks faced by the particular study
subjects) of the objective minimal risk standard (average risks faced by
normal healthy children) from section 50.51, this would clearly not meet the
risk level necessary for approval under the nontherapeutic risk category.
This likely situation, in which safe and effective treatment once again
exists for pediatric users, would also prevent approval of the placebo arms
of requested studies under the therapeutic research category described in the
previous section. Assuming the direct benefit criterion was satisfied by
providing only placebo, the risk-benefit ratio between placebo and currently
available alternatives would be approximately the same because the
currently available alternatives include no treatment, safe but ineffective
were signals of risk arising from some trials in other psychiatric indications (obsessive
compulsive disorder and social anxiety disorder) as well.").
174. FDA, FDA Public Health Advisory: Suicidality in Children and Adolescents Being
Treated with Antidepressant Medications, Oct. 15, 2004, http://www.fda.gov/cder/drug/
antidepressants/SSRIPHA200410.htm.
175. There are claims that the link between increased suicidality and the use of these
treatments in pediatric patients are overstated and not nearly the cause for concern that they
have been made out to be. See, e.g., Brent & Birmaher, supra note 2, at 379 ("the [British
Medicines and Healthcare Products Regulatory Agency] has overstated the risks and
underestimated the possible benefits of antidepressants for the treatment of pediatric
depression."). This may in fact be true, but this article will give the FDA's requests their
strongest case for legal approvability and ethical permissibility and thus assume that the
suicidality concerns are sufficient to create a situation in which there is currently no safe and
effective treatment for pediatric OCD and depression. But see, infra Part V.B.
176. See, e.g., Gandhi, supra note 120, at 296.
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treatment, or effective but unsafe treatment.
With the potential
development of a both safe and effective alternative for the treatment of
OCD and depression in children, the relation of the anticipated benefit of
placebo to the risk of non-treatment would no longer be "at least as
favorable to the subjects as that provided by available alternative
approaches. 17 7 Finally, with a safe and effective treatment available, the
placebo arm would not be approvable under the catchall established
bysection 50.54178 because it could not be conducted according to sound
ethical principles, as will be demonstrated in Part V below.
Therefore, when the federal risk categories are appropriately applied, the
placebo arms of the FDA's requested pediatric OCD and depression trials
will only be approvable until existing treatments or entirely new treatments
are proven safe and effective in light of recent suicidality concerns. These
placebo arms are certainly not minimal risk because these psychiatric
conditions in children require more stringent research protections than are
required under that category. The FDA categorizes placebo controls under
the therapeutic risk category based on a broad definition of "direct
benefit,, 179 although they are probably more appropriately classified as
nontherapeutic. At this time, the use of placebos for these studies is
probably approvable under either category because, absent a safe and
effective treatment, the placebo intervention presents a risk-benefit ratio
177. 21 C.F.R.§ 50.52.
178. 21 C.F.R. § 50.54 establishes criteria for the approval of research that poses more
than a minor increase over minimal risk, but offers no prospect of direct benefit and is thus
not approvable under §§ 50.51, 50.52, or 50.53. If an intervention or procedure is not
approvable under one of the other three categories, it may still proceed, but only if:
(a) The IRB finds and documents that the clinical investigation presents a
reasonable opportunity to further the understanding, prevention, or alleviation of
a serious problem affecting the health or welfare of children; and (b) The
Commissioner of Food and Drugs, after consultation with a panel of experts in
pertinent disciplines (for example: science, medicine, education, ethics, law) and
following opportunity for public review and comment, determines either: (1) That
the clinical investigation in fact satisfies the conditions of § 50.51, § 50.52, or §
50.53, as applicable, or (2) That the following conditions are met: (i) The clinical
investigation presents a reasonable opportunity to further the understanding,
prevention, or alleviation of a serious problem affecting the health or welfare of
children; (ii) The clinical investigation will be conducted in accordance with
sound ethical principles; and (iii) Adequate provisions are made for soliciting the
assent of children and the permission of their parents or guardians as set forth in §
50.55.
21 C.F.R. § 50.54.
179. The experimental arms of these studies would be appropriately approved under this
therapeutic category due to their potential for direct benefit regardless of whether there was a
safe and effective alternative, so long as the risk-benefit associated with the experimental
intervention was at least as favorable as the available alternative, essentially requiring
clinical equipoise. See infra Part V.A. 1.
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that is at least as favorable as that provided by available alternatives
(section 50.52), and it presents only a minor increase over minimal risk
(section 50.53). However, as soon as safe and effective therapy exists, the
placebo control arm will not satisfy either of these requirements and its use
would no longer be legally approvable.180 Nevertheless, pediatric research
for drugs to treat OCD and depression should not come to a standstill.
Instead, the FDA should replace its requests for placebo controls with
requests for active controls using the safe and effective treatment in all
future studies.18 Active controls would restore the conditions necessary for
IRB approval under Subpart D.
Assuming the FDA's requests for placebo controls to test drugs for the
treatment of pediatric OCD and depression are legally approvable now and
in the future, the question becomes whether the studies are ethically
acceptable. As Part V will demonstrate, the answer closely mirrors the
result obtained through this legal analysis, which demonstrates the moral
excellence of the federal regulations when stringently applied.
PART V-ARE THE REQUESTED PLACEBO-CONTROLLED PEDIATRIC
STUDIES ETHICALLY ACCEPTABLE?

The current lag in pharmaceutical development for pediatric patients
leaves children as therapeutic orphans and justifies the protective inclusion
of children in at least some research. However, the need for this research
must be weighed against ethical considerations. Its conduct must be
carefully planned and monitored to avoid ethical lapses that unduly risk
sacrificing the well being of some children for the good of others. With this
background in mind, an ethical analysis of the FDA's requested placebo
controls would permit placebo use during the initial safety trials following
the suicidality scare, but would require the use of active controls once there
is a safe and effective alternative.

180. This analysis demonstrates a relatively sharp break from the FDA's position,
considering that it requested placebo controlled studies for OCD drugs and antidepressants
even before the suicidality concerns were raised with regard to the drugs already approved
for these indications in children.
181. Some question exists as to whether the FDA could require active-controlled studies
instead of placebos or other designs in pediatric research, but this is really a non-issue in the
context of studies that are merely requested by the FDA under the BPCA in return for market
exclusivity because sponsors are not required to conduct the research and the statute gives
the agency authority to dictate the types of trials that will be responsive. The issue may be
more relevant in light of PREA, which actually requires pediatric research in some
circumstances, but even there, the FDA will likely have the authority to prescribe what types
of trials cannot be conducted given its current regulation of the sort of research that can be
approved by IRBs.
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A. When Are Placebo Controls GenerallyAcceptable?
1. The Need for Adequately Controlled Trials
The presence of a sound research design that does not impose
unnecessary risks on subjects is a fundamental consideration of research
ethics.1 82 Because research participants cannot be subjected to any level of
risk that will not personally benefit them, unless the results of the research
will be scientifically legitimate, 83 ethical research must address a
scientifically valuable "question by means of valid methods likely to
produce meaningful results."'' 8 4 Including control arms in the study design
contributes to the necessary validity by providing "a mechanism by which
to compare results from subjects taking an experimental intervention to
results from a group that is not receiving the treatment."' 85 This helps
establish that any change witnessed in the experimental arm is truly due to
the intervention and not to other confounding variables. Without a control
group, it would be virtually impossible to determine whether the
experimental treatment yields a favorable effect, a dangerous effect, or no
effect at all-in fact, controlled clinical trials are almost universally
recognized as "the best way science has come up with to determine what a
new drug really does.' 86
However, no concurrent control arm can be ethically included in clinical
research without the presence of clinical equipoise, which
demands that there be genuine uncertainty or disagreement in the expert
medical community about the relative merits of two or more therapies for
a given condition. An RCT [randomized controlled trial] is conducted to
resolve this professional uncertainty. This is the ethical equivalent of the
statistical dictum that an RCT must begin with an honest null hypothesis.
182. Wilfond, supra note 159. Avoidance of unnecessary risks involves ensuring that
the risks are proportionate to the likely benefits to subjects themselves and to the potential
for generalizable knowledge that will help future patients, maximization of subject safety,
equitable subject selection so that the burdens and benefits of research are fairly distributed,
protection of confidentiality and privacy, and informed consent (or assent and permission) is
obtained from all subjects or their legally authorized representatives. Id.
183. See CANCER MEDICINE 1005 (Robert Bast et al., eds. 5th ed. 2000) ("The scientific
methods used to conduct the study must be reliable and valid so that there is a reasonable
chance that the question asked will ultimately be answered. Trivial questions or invalid
methods cannot result in ethical research because no amount of risk or inconvenience to
subjects can be justified. Thus, bad science is inherently unethical science.") (footnotes
omitted).
184. Miller et al., supra note 132, at 105.
185. Hoffman, supra note 158, at 452.
186. Ken Flieger, Testing Drugs in People, FDA
2004, at 16, 16-17.
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While an individual physician may have a feeling that one arm of the trial
is preferable to the other, the absence187of consensus in the community
legitimizes enrolling patients in RCTs.

If clinical equipoise does not exist between the proposed experimental and
control interventions, the study cannot proceed. Lack of clinical equipoise
occurs either because the experimental treatment is generally accepted as
superior to the control, and so all subjects should receive that intervention,
or vice versa.
2. Types of Controls Available for Clinical Research
Assuming that equipoise is present, several types of controls are
available for well-designed, valid research.
First, historical controls
compare subjects given the investigational drug with similar patients treated
with a control drug at a different time and place, 88 or with data gathered
regarding the natural progression of the disease under study without any
treatment. 189 This study design provides all current subjects with the
experimental intervention and therefore removes the issue of withholding
potentially beneficial therapy.
However, historical controls are not
particularly effective because the design often cannot account for many
variables. The control arm may differ demographically from the current
experimental group because the two groups were not selected at the same
time or randomized from similarly situated individuals; also, the mere
separation in time can impact results. 90 For these reasons, historical
controls are not considered highly scientifically valid, although they may be
useful in studying diseases with high and predictable mortality rates.' 9'
Under those circumstances, any reduction could then be appropriately
attributed to the experimental drug.
Active controls, or "head-to-head" studies, are more useful than
historical controls, but they have their own limitations. This type of trial
design involves the concurrent randomization of potential subjects, with
one group receiving the experimental drug and the other receiving an active
drug known to be safe and effective. 92 Clearly, this requires the existence
of an alternative to the experimental intervention, which will not be the case

187.
188.
189.

CANCER MEDICINE,

190.

See Susan K. McCune, Creative Clinical Trials for PediatricDrug Development,

supra note 183 at 1005.
Flieger, supra note 186, at 17.
Hoffman, supra note 158, at 453.

http://www.fda.gov/cder/present/DIA2005/McCune.pdf
(last visited Sept. 29, 2006)
(discussing the advantages and disadvantages of clinical trials with external controls).
191. Id.
192. Hoffman, supra note 158, at 453.
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for the evaluation of first-line therapies. However, when an active
comparator is available, head-to-head trials offer several advantages. First,
because all subjects receive treatment, these trials avoid any ethical
problems associated with denying all therapy to a group of human subjects.
This advantage is especially important for children who cannot personally
consent to the refusal of such therapy outside of the research setting, a fact
93
that will become integral in the discussion of the FDA's requests below.
Also, active controls will generally provide more useful information to
doctors, patients, and third-party payors than placebo because active
controls can indicate whether an experimental drug is superior to existing
therapies,
as opposed to whether it is merely better than no treatment at
4
19

all.

Despite these benefits, active comparators have some practical
drawbacks. Most importantly, they could have significant placebo effects
of their own. 9' Therefore, even if the study seems to demonstrate an equal
level of benefit between the two groups, investigators cannot be certain that
either drug is actually effective. 196 This problem can be overcome if the
comparator used has already been determined effective in its own placebocontrolled trial, thus preserving the scientific validity of the current study
design. However, the high economic cost of active-controlled studies might
also present a problem for the pharmaceutical industry. 197 The increased
cost results at least in part from the necessary provision of active drugs to
both study arms, the requirement of larger sample sizes to counter any
variables stemming from the introduction of a second active drug, and the
longer amount of time needed to complete the study.198 Ultimately, the
FDA might hesitate in accepting these studies to prove safety and
efficacy. 99 Even more worrisome to drug sponsors than the costs is the
possibility that a head-to-head trial will expose a new drug as no better than

193.

See infra, Part V.C.

194. Comm. for Advanced Sci. Educ., Food & Drug Admin. Ctr. for Drug Evaluation &
Res., The Use of Placebos in Clinical Trials and the Ethics of the Use of Placebos, (Apr. 21,
1999), http://www.fda.gov/cder/foi/special/99/case-trans-42199.txt [hereinafter Comm. for
Advanced Sci. Educ.].
195. See Tamar Nordenberg, The Healing Power of Placebos, FDA CONSUMER
MAGAZINE, Jan.-Feb. 2000, at 14, 15 (describing the placebo effect in more detail: "[s]ham
medication can sometimes improve a patient's condition simply because the person has the
expectation that it will be helpful.").
196. Hoffman, supra note 158, at 456.
197. John March et al., AACAP 2002 Research Forum: Placebo and Alternatives to
Placebo in Randomized Controlled Trials in Pediatric Psychopharmacology,43(8) J. AM.
ACAD. CHILD & ADOLESC. PSYCHIATRY 1046, 1050 (2004).

198.
199.

Id.
Id.

http://lawecommons.luc.edu/annals/vol16/iss1/5

38

Fernandez Lynch: Give Them What They Want? The Permissibility of Pediatric Placebo

2007]

Permissibility of Pediatric Placebo-Controlled Trials

an existing drug, even if both are effective-precisely the reason that these
trials are so valuable to prescribers and payors.2 °°
Finally, placebo controls are largely accepted as the most efficient and
informative way to determine safety and efficacy of a drug, given the
natural variability among people. 20 1 This study design is widely considered
the scientific gold standard for clinical research.20 2 Using the placebo
control design minimizes both researcher and subject bias, thereby avoiding
the placebo effect that might otherwise confound data.20 3 Any statistically
significant difference between the placebo and experimental arm can be
clearly attributed to the active ingredient found within the experimental
drug because it is the only variable between the two groups. The FDA does
not require a drug study to include a placebo control; it does recognize,
however, that placebos can often
provide the clearest insight into what a treatment can accomplish,...
especially with some psychiatric and other drugs in which the placebo
effect is known to play a particularly weighty role. In fact,... in some
cases the placebo effect "makes it almost hopeless, statistically" to use
studies that test a new treatment side-by-side204against an existing one and
determine whether the new treatment works.
In addition to these validity benefits, placebo controls generally require
fewer subjects than a head-to-head study and are easier and less expensive
to conduct. 20 5 These benefits, combined with the eliminated risk of the
experimental drug proving to be less effective than existing therapy, 20make
6
this study design particularly attractive to the pharmaceutical industry.
However, placebo controls are not perfect. They have serious ethical
drawbacks when an effective active therapy exists that could be used as a
comparator. In these situations, subjects refuse a beneficial therapy and
potentially accept no clinically active therapy at all-the dummy pill. 20 7 This

200. Id.
201. Comm. for Advanced Sci. Educ., supra note 194.
202. Flynn, supra note 20, at 866.
203. McCune, supra note 190.
204. Nordenberg, supra note 195 (quoting Robert DeLap, M.D., head of one of the
FDA's Offices of Drug Evaluation).
205. March, supra note 197, at 1047.
206. See Lainie Friedman Ross & M. Justin Coffey, (Women and) Children First:
Applicable to Lifeboats? Applicable to Human Experimentation?, 6 J. HEALTH CARE L. &
POL'Y 14, 31 (2002) (stating that a trial that compares experimental medication against a
placebo shows a greater difference than a trial that compares an experimental medication
against a competitor. Consequently, the research can function as a medical advertisement to
increase market share and as groundbreaking research.).
207. Flynn, supra note 20, at 866; Comm. for Advanced Sci. Educ., supra note 194.
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ethical dilemma can often be overcome with variations on the standard
placebo-controlled design. For example, add-on studies combine placebo
and active controls so that one arm receives the standard or proven therapy
plus the test drug and the other receives the standard treatment plus a
placebo, thus avoiding the denial of treatment subjects would otherwise
receive outside of the research setting. 2°s Clearly, the add-on design is
impossible when there is no proven alternative or when administering
several drugs could be dangerous for dosing or interaction reasons. If these
problems are not present, however, this type of study is useful when it
would not be ethically appropriate to deny subjects the standard therapy.2 °9
Another approach involves enrolling only non-responders to available
therapy in placebo-controlled trials.2 10 This approach, however, introduces
its own confounder because these non-responders may be inherently
different from most patients who will eventually use the drug. 21' Finally,
researchers could attempt to limit exposure to ineffective treatment by using
early escape plans for those in the placebo group. 1 2 Early escape plans
would permit subjects receiving placebo to begin the experimental therapy
prior to the scheduled end of the trial if it is showing signs of efficacy in the
experimental group.213
Clearly, control groups are very important to appropriately conducted
pharmaceutical trials, but none of the existing alternatives flawlessly
combine scientific validity with ethical acceptability. Presumably due to the
status of placebo-controlled studies as the gold standard, however, the FDA
has requested these studies for OCD drugs and antidepressants in children.
The question that must now be addressed is whether these are ethically
appropriate or whether the FDA should instead shift its approach and
request one of the alternative controls described above.

208. Robert Temple, Overview of Placebo Control Trial Design: Benefits and
Difficulties, Meeting of the FDA's Pediatric Subcommittee of the Anti-Infective Drugs
Advisory Committee, Sept. 11, 2000, 40-41, http://www.fda.gov/ohrms/dockets/ac/0O0/
transcripts/364 It 1.pdf.
209. McCune, supra note 190.
210. Temple, supra note 208 at 42.
211. Id. This situation would be the same as when placebos are used in research for first
line therapies because subjects would not be denied treatments that are safe and effective for
them and would thus be no worse off if randomized to receive placebo.
212. Id.
213.

Id. at43.
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3. Ethical Analysis of the Use of Placebo Controls
a. No Safe and Effective Alternative
As implied above, placebo controls are not always ethically
problematic.2 14 In fact, when there is no proven treatment available, and
researchers are genuinely uncertain as to whether the study drug will be
more effective (or more dangerous) than no treatment at all, placebo use is
permissible in both adult and child subjects. 215 This will often be the case
in pediatric research, where the lack of proven therapies is precisely what
makes the research so vital.21 6 The lack of proven therapies also renders
alternative study designs impossible and necessitates placebo use to
generate valid scientific results. The best placement for a patient might
even be in the placebo arm of a trial because "those who receive placebos in
clinical drug studies avoid exposure to the potential hazards of the therapy
being tested although they might receive no benefit from the inactive
agent., 21 7 Both the American Academy of Pediatrics and the FDA's
Pediatric Advisory Subcommittee agree that placebo controls are
permissible in pediatric research so long as their use does not place children
at increased risk; in other words, placebo controls are acceptable when there

214. March et al., supra note 197, at 1053.
215. Some considerations normally taken into account to determine whether placebos
are desirable and acceptable as a control in a randomized clinical trial include: (1) existing
evidence of efficacy and safety for the medication to be studied-the weaker the evidence,
the more desirable it is to include a placebo; (2) stability of the disease to be treated-the
greater the expected natural fluctuation of symptoms, the more desirable the use of placebo
becomes because it would otherwise be difficult to determine whether the change is due to
the disease itself or the drug; (3) the known range of placebo response in the same condition
and type of medication-the wider the range of response is, the more need for placebo
controls to truly establish that a placebo effect is not responsible for changes noted in the
experimental group; (4) the risk of harm from withholding active treatment-the greater
potential for harm, the less acceptable is the use of placebos; (5) the rescue procedures to
minimize possible negative consequences from placebo use-the more liberal the provisos
for adding active treatment in response to symptom worsening or lack of improvement, the
stronger the acceptability of placebo; and finally, (6) the potential for direct benefit from
placebo-the greater the potential benefit from placebo compared with direct benefit from
trial participation or receiving the active treatment, the more acceptable is use of placebo.
Id. at 1053-54.
216. Am. Acad. of Pediatrics, supra note 4, at 286-87. Recall that the "nonvalidated
administration of medications may place more children at risk than if the drugs were
administered as part of well-designed, controlled clinical trials." Id. See also Rosato, supra
note 30, at 363 (stating "[w]hether children are included in trials or prescribed drugs off
label, similar risks are taken. The reality of this Hobson's choice should inform any ethical
framework that is created.").
217. Hoffman, supra note 158, at 477.
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is no commonly accepted therapy for the condition or when that therapy is
of questionable efficacy or is dangerous.2 18
Of course, the argument remains that it is still unethical to include
children in placebo-controlled research, even if they are not being denied
any safe and effective therapy, because they will not benefit from their
participation. Arguably, these children are being used merely as a means to
an end.2 19 While this strong deontological point strikes at the foundation of
all nontherapeutic research, as Subpart D appropriately recognizes, the
situation truly leaves no other choice: the research must be done for
medicine to advance. This utilitarian justification will fail to convince all
critics, 22 and the deontological approach should prevail when there are
alternatives that avoid using children as a mere means to the development
of treatment options. Whether people should sacrifice themselves for the
greater good becomes significant in situations where placebo controls may
be permitted among adult subjects.
b. Safe and Effective Alternatives to Placebo-AdultSubjects
In adult research, placebo controls may be ethically utilized despite the
existence of a safe and effective alternative, depending only on the consent
of the adult subject and severity of the condition at issue. For this subject
population, it is "generally accepted practice in the United States... that
well and fully informed patients can consent to take part in a controlledrandomized-blinded clinical trial, even when effective therapy exists, so
long as they are not denied therapy that could alter survival or prevent
irreversible injury., 221 When an effective therapy is available, one of the
biggest problems facing placebo controls is the difficulty justifying the
unfavorable risk-benefit ratio. The decision to refuse effective therapy

218. Am. Acad. of Pediatrics, supra note 4, at 294. Similarly, the FDA Pediatric
Advisory Subcommittee stated that "[p]lacebo controlled trials may be acceptable if there are
no approved or adequately studied therapies for children with the condition under study."
FDA, FDA Pediatric Ethics Working Group Consensus Statement on the Pediatric Advisory
Trials,
2000
Meeting, Placebo Controlled
September
11,
Subcommittee's
http://www.fda.gov/cder/pediatric/ethics-statement-2000.htm [hereinafter Pediatric Ethics
Working Group]. The FDA would also permit add-on placebo controlled trials that do not
deny subjects any element of the standard of care. Id. However, the AAP would permit
placebos alone "when the incidence and severity of undesirable side effects produced by
adding a new treatment to an established regimen are uncertain." Ross & Coffey, supra note
206 at 26.
219. Hoffman, supra note 158, at 476.
220. See generally, supra notes 157-61 (discussing nontherapeutic research in pediatric
subjects and the related utilitarian-deontological conflict).
221. Flieger, supra note 186, at 18. See also Hoffman, supra note 158, at 451-52.
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carries a substantial risk while receiving only placebo is likely to have no
direct benefit, which creates a wide gap between what could be expected in
the clinical care and research settings. However, when the condition under
study is not particularly severe, the risk-benefit ratio of refusing a proven
drug is less problematic because both the benefit of treatment and the risk
of non-treatment are relatively insubstantial. In the latter situation, an
autonomous and informed decision to participate in placebo-controlled
research is all that is necessary for placebo use to pass ethical muster.222
While this approach may raise concerns about disregarding the
professional duty of physicians to provide the best care for their patients,
physicians have different responsibilities in the research setting. They are
no longer engaged in a doctor-patient relationship, but rather in a
researcher-subject relationship. 3 Here lies a critical distinction. In
standard practice, classic fiduciary duties apply and a physician's primary
loyalties must be focused on the health and well-being of the individual
patient. 224 In research, the investigator's allegiance is to the protocol and
the creation of generalizable knowledge, with the limitation of ensuring
subject safety to the greatest extent possible.2 25 The investigator has no
obligation, or even ability, to tailor the protocol to the interests of individual
subjects. 226 Even in the standard clinical setting, patient autonomy holds a
position of utmost importance, and the physician's duty to treat yields to the
patient's informed, competent refusal of care. Treatment against a patient's
wishes is classic battery, even if the physician's intervention is beneficial.22 7
Focusing on the consent of the adult subject in determining the ethics of
placebo controls does no damage to the professional ethics of physicians
because it merely recognizes a current physician duty.
222. Hoffman, supra note 158, at 479.
223. See E. Haavi Morreim, Litigation in Clinical Research: Malpractice Doctrines
Versus Research Realities, 32 J.L. MED. & ETHICS 474, 475-77 (2004) (providing a detailed
discussion of the differences between a physician in the clinical care context and a
researcher, who also happens to be a physician).
224. Id. at 447.
225. Id. ("The investigator does not owe his top loyalty to the subject in the same way a
physician owes his to the patient.").
226. Id. The differences between the ethical responsibilities contribute to the
therapeutic misconception, discussed infra note 23 1, and the associated belief that the
researcher is truly looking out for the best interests of the subjects, rather than for the
advancement of science. Hoffman, supra note 158, at 482.
227. E.g., Schloendorff v. Society of New York Hospitals, 105 N.E. 92 (N.Y. 1914)
(explaining that a doctor removed a tumor after the patient had consented to an abdominal
exam under anesthesia, but had specifically requested that there be no operation. The court
stated, "[e]very human being of adult years and sound mind has a right to determine what
shall be done to his own body," and held that a doctor is liable for battery by touching
without consent, despite the fact that the touch might be in the patient's best medical
interests.).
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The inverse relationship within this consent/severity model requires that
permission to the adult subject to consent must be progressively scaled back
as the risks associated with the underlying condition become more serious.
For example, individuals experiencing male pattern baldness could be
ethically enrolled in a placebo-controlled trial of an experimental new
therapy despite the existence of Rogaine because the result is merely
continuing baldness, a purely cosmetic problem that does not impair the
subject's capacity to consent.22 8 The same is true for adult sufferers of
routine headaches. Patients who receive placebo may experience some
discomfort, but they do not risk lasting health detriments; this establishes a
situation where "an [adult] individual's prerogative [is] to say, 'I229know
what I'm getting into, and I want to further this scientific research. '5
The risks of life-threatening cancer, on the other hand, are so severe that
they may not be overcome by the consent of an adult subject to potential
randomization in a placebo arm,230 even if that patient could consent to
refusal of treatment outside of the research setting. This is partially because
research is an entirely different animal than clinical practice, an issue that
will be addressed in more detail below. The ability of any patient suffering
from a severe disease to fully comprehend the information necessary to
enroll in research that will not provide him with personal benefit is
uncertain. The tyranny of the disease causes this question; these patients
might be desperate, may selectively internalize information, and might not
ultimately comprehend their chances of receiving placebo rather than the
active, but experimental, intervention.2 31
Strong proponents of individual autonomy argue that subjects should be
able to consent to any level of risk, without limitation based on the severity
of their underlying condition. Generally, though, the research community
takes the stance that the potential benefit must justify the level of risk the
study presents.232 The level of risk posed by placebo use for severe
228. Temple, supra note 208, at 21.
229. Nordenberg, supra note 195, at 17.
230. Id. ("In ...oncology, placebo-controlled studies are often unacceptable because of
the great risk to cancer patients of any treatment delays.").
231. Hoffman, supra note 158, at 482-83. Many subjects do not comprehend that the
research will probably be of no benefit to them personally, nor that the researchers are
focused on the welfare of future patients rather than current subjects. For example, many
subjects who are clearly told that they are involved in a placebo-controlled study still believe
that they will benefit and that researchers always act in the subject's best medical interest.
Id. at 482. This misconception is clearly more problematic when subjects are suffering from
more severe ailments, which is precisely why the use of placebo controls in the face of safe
and effective treatment is permissible only for mild conditions where even if the subjects
failed to understand the protocol, that misunderstanding would not be terribly detrimental.
232. 21 C.F.R. § 56.111 (2006) (requiring IRBs to balance the risks and benefits of
research when determining approval).
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ailments when a safe and effective alternative exists cannot be balanced by
the benefits offered to the individual subjects who might receive those
placebos. Several governmental and international sources agree and have
adopted the severity/consent model for the ethical review of placebocontrolled research.
For example, the FDA and its representatives have stated that placebos
are generally acceptable so long as subjects are not denied existing lifeprolonging treatment 233 and would not risk serious and irreversible harm by
taking them.234 When effective treatment exists, the Canadian government
permits placebo controls so long as subjects have provided an informed
refusal of standard therapy for a minor condition for which patients
commonly refuse treatment; further, withholding such treatment must not
have the possibility of any magnitude of irreversible harm.2 35 The
Declaration of Helsinki states a preference for active controls whenever
possible,2 36 but provides in a footnote that placebo controls might be
permissible even when proven therapy exists if there are "compelling and
scientifically sound methodological reasons" for their use.2 37 Moreover,
placebo controls may be used if a "prophylactic, diagnostic or therapeutic
method is being investigated for a minor condition and the patients who
receive placebo will not be subject to any additional risk of serious or
irreversible harm., 238
Finally, the International Council for
Harmonization's Guideline ElO permits enrollment of subjects in placebocontrolled trials even if proven therapy exists, as long as the risk of nontreatment involves only discomfort.23 9
In summary, there is widespread agreement that competent adult subjects
should be permitted to submit to some low level of research risk by refusing
proven therapy in favor of potentially receiving no more than placebo.
233.

Cohen, supra note 95, at 696.

234. Comm. for Advanced Sci. Educ., supra note 194.
235. Cohen, supra note 95, at 697. Canadian research ethics and regulation also permit
placebo controls in the previously discussed situations, such as when there is no standard
treatment, standard therapy has been shown to be no better than placebo, there is evidence
creating substantial doubt regarding the net therapeutic advantage of standard therapy,
effective treatments are not readily available to patients (subject to considerations ofjustice),
subjects are refractory to standard treatment and no second-line treatment exists, or in add-on
trials. Id.
236. WORLD MED. ASS'N, supra note 121, at paragraph 29 (stating "benefits, risks,
burdens and effectiveness of a new method should be tested against those of the best current
prophylactic, diagnostic, and therapeutic methods. This does not exclude the use of placebo,
or no treatment, in studies where no proven prophylactic, diagnostic or therapeutic method
exists.").
237. Id. atn.1.
238. Id.
239. Temple, supra note 208, at 23-24.
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Conversely, patients with severe conditions may bear added vulnerabilities
as a result of the disease and researchers should not present them with the
option of research that hazards the denial of treatment and its consequent
risks.
c. Safe and Effective Alternatives to Placebo-ChildSubjects
Several ethical guidelines and commentators extend the severity criteria
that justify placebo controls in adult research to pediatric studies as well.
This allows the inclusion of placebo arms even when proven therapies,
specifically approved and labeled for use in children, exist. In fact, "many
bioethicists and pediatric psychopharmacologists believe that placebocontrolled trials are ethical in the pediatric population even when known
effective therapies are available as long as the subjects in the trial will not
be harmed by deferral of existing therapy. 2 40 Some rely on analysis of
protocols under the federal regulations, arguing that for mild conditions,
withholding effective treatments can be categorized only as a minor
increase over minimal risk.241
The FDA's Pediatric Advisory Subcommittee has indirectly expressed
support for the use of placebo-controlled pediatric research of drugs to treat
mild afflictions, stating that "[i]n placebo controlled studies of minor
illnesses and symptomatic conditions, exposure to placebo and patient
discomfort can often be minimized by use of a randomized withdrawal
design, usually with defined individual patient discontinuation criteria
(escape rules) so that the time of exposure to ineffective treatment is
minimized., 242 Though this statement does not specifically address
situations in which a proven therapy exists as an alternative, it demonstrates
the FDA's willingness to categorize pediatric trials based on the severity of
the condition at issue, as do its requests for placebo controls to study drugs
243
used to treat psychiatric disorders, but not for HIV and oncology drugs.
Physicians also seem to have fallen prey to the difference between
research on mild and severe pediatric conditions. The American Academy
of Child and Adolescent Psychiatry (AACAP) has stated that "placebocontrolled trials must not be used if safer and equally effective research

240.

March et al., supra note 197, at 1047.

241.

Rosato, supra note 30, at 372.

Regardless of whether the condition is mild or

severe, however, denial of a safe and effective alternative in favor of placebo exposes child
subjects to risks that are more than minimal. See infra Part IV.B.3.
242. Pediatric Ethics Working Group, supra note 218.
243. See Comm. for Advanced Sci. Educ., supra note 194 (noting that the FDA will not
request a placebo controlled study for serious conditions that will create risk of death or
irreversible morbidity, but will request them for less risky conditions and diseases).
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This
technologies are available to answer the scientific question." 24
position appears to favor head-to-head trials whenever possible because
they would unquestionably be safer, although the data from these trials may
only be as useful as the data obtained through the use of placebo controls.24 5
Nevertheless, the AACAP encourages placebo controls when "needed to
answer appropriate and necessary scientific questions and when the risk is
acceptable. In short, placebo controls are ethically justifiable when they are
and do not expose research participants to
supported by rigorous science
246
excessive risks of harm.,

Despite these indications, however, analysis of the ethical permissibility
of placebo control arms in children is not appropriately based on
consideration of the severity of the condition under study because pediatric
subjects lack the correlate to that consideration in adults-the capacity to
consent. The severity/consent model has its foundation in the autonomy of
adult subjects,247 and this principle does not apply to children. As
skydivers, the tattooed, and cyclists without helmets demonstrate,
competent and mature adults can choose to partake in behavior and
activities that subject them to a wide range of risks. The independence of
adults to make their own decisions is widely respected, so long as their
actions will not cause harm to others.248 When the level of risk that adult
subjects can be exposed to in the research setting is limited, for example by
permitting placebo controls to replace proven therapy only for minor
conditions, it is not because the principle of autonomy no longer applies.
Rather, limitations exist because there are certain situations in which a
person's capacity to make a rational decision will be questioned-their
autonomy is weakened.
In the research setting, IRBs, like the managers of tattoo shops, serve a
gate-keeping role in which they determine what level of risk can be offered
to potential research subjects, regardless of whether those individuals claim
to be personally willing to accept more extensive dangers. 49 If legally
competent (or by decision of a surrogate), an adult patient may refuse
244. March et al., supra note 197, at 1048.
245. See supra Part V.A.2.
246. March et al., supra note 197, at 1048.
247. Smolin, supra note 3, at 622.
248. Id.
249. Under federal regulations, before an IRB can approve proposed research, it must
determine, among other things, that "(1) Risks to subjects are minimized: (i) By using
procedures which are consistent with sound research design and which do not unnecessarily
expose subjects to risk, and (ii) whenever appropriate, by using procedures already being
performed on the subjects for diagnostic or treatment purposes" and "(2) Risks to subjects
are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of
the knowledge that may be expected to result." 21 C.F.R. § 56.111.
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clinical care for his or her condition regardless of the condition's
severity.25 0 That same patient, however, could not enroll in a placebocontrolled study of a drug to treat a severe condition. This limitation of
patient autonomy demonstrates an important distinction between medical
care and research.
To review, though adults' ability to consent to research risks can solve
many of the ethical problems associated with clinical studies (up to a cutoff point established by IRBs), the same is not true for children. Children
lack the maturity needed to make many decisions for themselves and their
autonomy is not afforded the same respect and deference provided to
adults. 25 1 Instead, decision-making power often resides with parents, who
are generally permitted to make choices about their child's welfare within a
wide range of acceptability. Importantly, Subpart D substitutes the notion of
informed consent with a combination of parental permission ("the
agreement of parent[s] or guardian[s] to the participation of their child or
252 and assent ("a child's affirmative
ward in a clinical investigation")
25 3
participate").
to
agreement
Admittedly, this is not perfectly equivalent to the consent used to
validate the severity model for the permissible use of placebo controls in
adult research. In pediatric studies,
[tihe refusal to use the term "consent" in relation to parents and children
underscores the lack of an autonomous, legally competent research
subject; the rationales for seeking "parental permission" and the "assent
of children" therefore are distinct from the rationale254 for seeking
"consent" from a legally-competent adult research subject.
This imperfect replacement of informed consent with the assent/permission
requirement for children is further demonstrated by the limited
circumstances under which adult consent to participate in research can be
waived, as in the case of a life-threatening emergency when no legally
authorized representative can be found and the research would be otherwise
impossible to conduct.255 Conversely, assent is far more easily waived
250. See Cruzan v. Director, Missouri Dept. of Health, 497 U.S. 261, 278-89 (1990)
(recognizing that the right to privacy and the right to consent to medical treatment also create
a right to refuse care).
251. See Parham v. J.R. et al., 442 U.S. 584, 603 (1979) (stating "[m]ost children,
even in adolescence, simply are not able to make sound judgments concerning many
decisions, including their need for medical care or treatment. Parents can and must
make those judgments.").
252. 21 C.F.R. § 50.3(r) (2006).
253. 21 C.F.R. § 50.3(n) (2006).
254. Smolin, supra note 3, at 631.
255. See 21 C.F.R. §§ 50.23-50.24 (2006) (explaining the conditions under which adult

http://lawecommons.luc.edu/annals/vol16/iss1/5

48

Fernandez Lynch: Give Them What They Want? The Permissibility of Pediatric Placebo

2007)

Permissibility of Pediatric Placebo-Controlled Trials

because it may be impossible to obtain from very young children, and
researchers can avoid the requirement to obtain assent for minimal risk
research and certain types of direct benefit studies.256
Notably, researchers cannot easily avoid the parental permission
257
requirement. 25
Parental permission is closer to the equivalent of consent
because parents are the ones provided with all of the information and forms
that would usually be given to the competent adult subject. However,
relying solely on parental permission still creates a situation in which
someone other than the subject chooses whether to accept the risks and
benefits of research participation. Despite the protections of requiring
parental permission, the reliance on parents as decision-makers differs
greatly from the evaluative process in the consent/severity model applied to
adults.
American society and jurisprudence share a long history of protecting the
ability of parents to make choices about which activities or experiences are
desirable or beneficial for their children without interference from the
government, outside of exceptional circumstances.2 58 Clearly, parents are
given broad latitude to determine which risks their children are exposed to
on a daily basis and they are generally the best people to make those
decisions that children lack the capacity to make on their own. With
decisions about pediatric medical care and participation in research, parents
are the next best thing to a decision made by a competent patient or subject
consent may be waived).
256. See 21 C.F.R. § 50.55 (describing when the assent of child subjects must be
solicited and when it may be waived).
257. See Efi Rubinstein, Comment, Going Beyond Parents and Institutional Review
Boards in ProtectingChildren Involved in NontherapeuticResearch, 33 GOLDEN GATE U. L.
REV. 251 (2003) (describing when federal regulations permit research without parental
permission, including situations of abuse, emancipated and mature minors, and research on
conditions that minors could consent to treatment for on their own, such as sexual assault,
pregnancy, drug and alcohol abuse, and the like).
258. Glantz, supra note 40, at 220. Other commentators have also noted that it makes
sense that the permission of at least one parent is a minimum requirement for enrollment of
children in clinical research because
[i]t is a long-standing tradition in the Western world that parents have
tremendous discretion to make decisions for their children regarding a whole
range of very important matters. It is parents, after all, who make or facilitate
decisions concerning a child's education, religion, habits, sexual initiation,
etc. This is perhaps even more true in the context of medical treatment. The
law generally acknowledges that parents are in the best position to determine
what sort of treatment is best for the child and the family and, not trivially,
that parents must significantly bear the untoward consequences of a failed
therapeutic attempt.
Randall Baldwin Clark, Speed, Safety, and Dignity: PediatricPharmaceuticalDevelopment
in an Age of Optimism, 9 U. CHI. L. SCH. ROUNDTABLE 1, 25 (2002) (internal citations
omitted).
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him or herself,259 and choices by parents among reasonable alternatives are
widely respected. However, their discretion is certainly not unfettered. 6 °
The government may fill the gaps in pediatric autonomy through general
restrictions on the activities of children that even parents cannot overcome.
Examples include mandatory safety seat and helmet laws for children under
a certain age and laws prohibiting sexual contact with minors. 26' A
somewhat surprising, but strong, analogy exists between statutory rape laws
and government intervention in the type of research in which parents may
enroll their children. The state may freely determine that children below a
certain age cannot consent to participate in sexual activity, even if they
might choose to participate when they reach adulthood, because of the
possible physical and emotional risk to the child. Importantly, parents
cannot preempt laws that prohibit statutory rape by giving their children
permission to have sex with adults, even if they help ensure that the sexual
conduct is "safe." Similarly, the government could conclude that research
denying child subjects safe and effective treatment for OCD or depression
is so risky that children cannot enroll, even if they would choose to enroll in
such research as adults and even if their parents would allow the
enrollment. The same analogy applies with government action that forces
children to attend school, prevents them from being employed, or prohibits
them from holding certain jobs like exotic dancing, bartending, coal mining,
factory work, and other morally or physically risky occupations.262
With regard to medical decision-making for children, the government
cannot intervene simply because the parents' choices may be disagreeable
to the child or because they involve some risk.263 At the same time, parents
are not free "to make martyrs of their children before they have reached the
age of full and legal discretion where they can make that choice for
themselves. ' '26
Courts historically have been amenable to parental
259.

Rubinstein, supra note 257, at 277-78.

260. Clark, supra note 258, at 25 (noting that "parental dominion over children is not
unlimited. The state limits corporal punishment, requires a certain form of education for
a specified term of years, restricts the type of labor that children may perform, prohibits
incest, and, not insignificantly, requires parents to emancipate their children at the age
of eighteen.").
261. E.g., Jenna Merten, Raising a Red Card: Why Freddy Adu Should not be Allowed
to Play ProfessionalSoccer, 15 MARQ. SPORTS L. REv. 205 (2004).

262. See generally Sy Moskowitz, American Youth in the Workplace: Legal
Aberration, FailedSocial Policy, 67 ALB. L. REv. 1071 (2004).
263. Parham v. J.R. et al., 442 U.S. 584, 603 (1979).
264. Prince v. Massachusetts, 321 U.S. 158, 170 (1944). See also Glantz, supra note 40,
at 220 (explaining that the scope of parental authority is "more questionable when the parent
is agreeing to a risky intervention.. that cannot possibly benefit the child," but where there
is some possibility of benefit, parents are generally left to balance risks and benefits in daily
life).
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decisions to withhold treatment for a variety of significant, but non-fatal,
medical conditions, such as surgeries to repair a cleft palate or non-fatal
spinal degeneration. However, courts would almost "invariably intervene
when parents refused to consent to life-saving treatment[s] of proven
effectiveness and trivial risk" for their ailing children.26 5 Extending this
argument, parents should be similarly unable to reject safe and effective
life-saving therapy for their children in favor of enrollment in placebocontrolled research. This result mirrors the severity distinction in adult
subjects, where placebo controls are ethically impermissible when proven
treatment for severe conditions exists.
A larger issue is whether parents can refuse treatment on behalf of their
children who suffer from milder, non-life-threatening conditions. Though
refusal in such situations has historically been permitted in deference to
parental decision-making, courts have begun to intervene in some of the
more egregious situations in which children suffer from serious, but nonlethal, impairments, such as the "elephant man disease," or
neurofibromatosis.266 Again, parents cannot choose placebos for their
children in response to these relatively severe health problems, in line with
the adult severity distinction. Furthermore, courts have also ordered that
children receive necessary dentistry2 67 and tonsillectomies2 68 over the
objections of the parents. It is unclear precisely which conditions will be
considered sufficiently mild for parents to refuse all treatment for their
children without state interference. 69 Parents can withhold something as
minor as headache medicine or cough syrup from their child with no more
intrusion than, perhaps, social condemnation from other parents. Yet a
strong argument remains that parents should not be able to enroll those
same children in placebo-controlled research in which they still might
receive no treatment for these or other mild health problems.
At first glance, this argument may seem counterintuitive. After all, why
not allow children who would not be given treatment anyway to receive

265. Clark, supra note 258, at 25.
266. Id.
267. In re Gregory S., 380 N.Y.S.2d 620 (N.Y. Fam. Ct. 1976).
268. In re Karwath, 199 N.W.2d 147 (Iowa 1972). However, a court will not order that
a child undergo risky, invasive, or life-threatening treatment for a non-emergency, non-lethal
condition. 59 AM. JUR. 2D PARENT AND CHILD § 19 (2006).
269. See LaDonna DiCamillo, Caught Between the Clauses and the Branches: When
Parents Deny Their Child Nonemergency Medical Treatment for Religious Reasons, 19 J.
Juv. L. 123, 123-24 (1998) ("Courts have consistently permitted state intervention in
cases where the child's life is threatened. Likewise, courts typically hold parents
criminally responsible for the negligent death of a child whose parents fail to seek
adequate medical treatment. There is a split of opinion, however, as to whether
intervention is constitutional in nonemergency cases.") (internal citations omitted).
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only a placebo? In fact, this closely resembles the situation described above
allowing parents to enroll their children in placebo-controlled research
when no safe and effective therapy exists because the children would not be
denied anything they would otherwise receive. The same is true here, but
only artificially because the parents are denying treatment that does exist
and to which the children would otherwise have access but for their parents'
interference. The two situations should be treated differently because of the
major distinctions between clinical care and research. Some of these
differences were introduced above, but the bottom line is that regardless of
what choices parents can make for their children based on religious or other
beliefs in the ordinary medical context, the research environment has a
built-in gatekeeper: the IRB.
These boards are a form of mandated government intervention from the
very outset of research 270 that is simply not present in other areas of life,
including decisions about standard medical care. Moreover, they have the
ethical obligation to protect subjects as much as possible while allowing
needed research to move forward.27 1 IRBs can determine standards for
enrollment that differ from what adult subjects, or parents of child subjects,
believe to be appropriate. Just as an IRB may refuse to permit adult cancer
patients to enroll in placebo-controlled research, even if that patient has
refused all available therapies, the IRB may also establish a more stringent
best interest standard applicable to pediatric research. IRBs may do so even
if that same standard might violate religious freedom and general parental
control if applied to the clinical setting. The difference exists because
human research is a take-it-or-leave-it proposition in which subjects or their
guardians have the legal rights to refuse to enroll if they disagree with the
protocol or enrollment criteria and to withdraw from participation at any
time.272 Still, there is no legal right to demand changes to those elements
that remain purely under the IRB's control.
Although subjects have the "right to choose in light of their values
whether or not to participate in an approved research project, researchers
and independent reviewers have an obligation to not approve and conduct
research when, in light of their values, the benefits of the research are
insufficient to justify its risks. 27 3 Some may argue that potential subjects
270. Aside from minor exceptions, clinical trials submitted to the FDA in support of an
application for approval "shall not be initiated unless that investigation has been reviewed
and approved by, and remains subject to continuing review by, an IRB meeting the
requirements of this part." 21 C.F.R. § 56.103 (2006).
271.
BARUCH BRODY, THE ETHICS OF BIOMEDICAL RESEARCH: AN INTERNATIONAL
PERSPECTIVE 49 (1998).

272.
273.

21 C.F.R. § 50.25(8) (2006).
BRODY, supra note 271.
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have a moral right to research participation to obtain access to needed
experimental therapies, and that IRBs have a responsibility to expand
enrollment criteria and avoid arbitrary or discriminatory exclusions.
However, such a claim certainly does not extend to access to placebos. 74
For these reasons, concerns about religious freedom do not present a barrier
to the exclusion of children from placebo-controlled research on drugs to
treat relatively mild, non-fatal conditions for which safe and effective
treatment exists.275 However, the question remains of why this exclusion is
morally necessary for pediatric subjects, but not for adults.
As discussed above, parents make decisions for their children because
children lack the developmental and legal capacity to make the decisions
for themselves. While parents might have an idea of what choices their
children should make when they reach a competent age, parents truly lack
the background information that serves as the basis for substituted judgment
as applied to previously competent individuals; unlike adults who have lost
their competence to consent, children never had such competence.
Therefore, parents cannot extrapolate from a child's prior decisions to
determine what the child would decide if currently competent to do so.
When there is no such background information, either for the adult who was
never competent or the child, the decision of which treatment course to
pursue or whether to enroll in research should be based on the best interests
of the patient or potential subject, focusing on the outcome that would best
promote his or her individual well-being.276 Clearly, there may be
reasonable disagreement as to which choices will truly be in the child's best
interest. While IRBs could certainly impose a very strict view to protect
child subjects as much as possible, even the normal moral standard to which
parents are held sufficiently prohibits the enrollment of children in placebo-

274.

See M.L. Elks, The Right to Participate in Research, 122(2) J. LAB. CLINICAL.

MED. 130 (1993) for a general discussion of the moral right to participate in research.

275. There is no right under the Constitution's religion clauses that protects secular
beliefs, and thus neither adult subjects nor the parents of child subjects could claim that their
free exercise rights were violated if they had some strongly held, but non-religious,
commitment to participation in all types of clinical research or devotion to the progress of
science that was hampered by an IRB refusing to permit them or their child to enroll in a
study for any reason. See 16A AM. JUR. 2D CONSTITUTIONAL LAW § 424 (2006) (stating
"[o]nly beliefs rooted in religion are protected by the Free Exercise Clause of the First
Amendment, which, by its terms, gives special protection to the exercise of religion.
Religious beliefs need not be acceptable, logical, consistent, or comprehensible to others in
order to merit First Amendment protection. However, the Free Exercise Clause does not
protect purely secular views or personal preferences." (footnotes omitted)).
276. See Stephen A. Talmadge, Who Should Determine What Is Best for Children in
State Custody Who Object to Psychotropic Medication?, 15 ANNALs HEALTH L. 183, 191
(2006) (noting that a "decision that is to be made on an incompetent patient's behalf should
advance the individual's best interests.").
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controlled research for any condition, including relatively mild ones, when
there is a safe and effective alternative.
Parents are not obligated to act in the objective best interests of their
277
children, mostly because such an objective standard does not exist.
However, parents do have a moral responsibility to act only in a manner
that, at least arguably, furthers their child's welfare.278 Applying this
standard to pediatric research, when safe, effective, and proven treatment
exists for the condition under study, a child's best interest will never be to
receive no treatment instead of the effective treatment, regardless of how
mild the condition might be.
In a decision highly criticized for its poor understanding of the conduct
of scientific research and its disregard for common conceptions of research
ethics, Maryland's highest court held in 2001 that "a parent, appropriate
relative, or other applicable surrogate, cannot consent to the participation of
a child or other person under legal disability in nontherapeutic research or
studies in which there is any risk of injury or damage to the health of the
subject., 279 Application of this sweeping statement would severely limit the
progress of pediatric medicine and continue the problem of therapeutic
orphaning by ignoring the federal regulations that permit essential
nontherapeutic research (described in Part IV above). The court retreated
slightly from this holding in its response to a motion for reconsideration,
defining "any risk" as "any articulable risk beyond the minimal kind of risk
that is inherent in any endeavor" and noting that the "context of [its
previous statement] was a nontherapeutic study that promises no medical
benefit to the child whatever, so that any balance between risk and benefit is
necessarily negative., 280 However, regardless of whether the court
ultimately reached the appropriate result or did in fact go too far, it did
make a valid and applicable point to the discussion here:
Whatever the interests of a parent, and whatever the interests of the
general public in fostering research that might, according to a
researcher's hypothesis, be for the good of all children, this Court's

277. Am. Acad. of Pediatrics, Committee on Bioethics, Informed Consent, Parental
Permission,and Assent in PediatricPractice,95 PEDIATRICS 314, 315 (1995) ("Usually,
parental permission articulates what most agree represents the 'best interests of the child.'
However, the Academy acknowledges that this standard of decision-making does not always
prove easy to define. In a pluralistic society, one can find many religious, social, cultural,
and philosophic positions on what constitutes acceptable child rearing and child welfare.").
278. See Glantz, supra note 40, at 219 (stating "parents must meet a standard of
adequacy, not excellence.").
279. Grimes v. Kennedy-Krieger Inst., Inc., 782 A.2d 807, 858 (Md. 2001).
280. Id. at 862. This statement fails to solve the problem because it seems to still
prohibit nontherapeutic research approvable under 21 CFR § 50.53.
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concern for the particular child and particular case, over-arches all other
interests. It is, simply, and we hope, succinctly put, not in the best
interest of any healthy child to be intentionally put in a nontherapeutic
situation where his or her health may be impaired, in order to test
methods that may ultimately benefit all children. 2l
While the facts of this particular case limited the court's discussion to
healthy subjects, its statement can easily be extended with a few
modifications: it is not in the best interest of any child to be intentionally
put in a nontherapeutic situation where his or her health is needlessly
impaired through use of placebo rather than available, proven, and active
treatment.
For placebo-controlled pediatric research when there is no safe and
effective treatment, the child's situation is the same both in and out of the
research program. This situation is not an artificial similarity imposed by
the child's parent withholding beneficial therapy. The child will have an
untreated condition whether he participates or not because there is no
alternative that would improve his circumstance, and there are no
differential interests to compare. However, when there is a feasible
alternative therapy, for example, for a child's headache, no one argues that
it is in that child's best interest to continue to suffer even minor and
temporary discomfort. The child should be given the available headache
medicine in both clinical care and in research, and thus the use of placebos
for child subjects facing even such mild conditions is ethically
impermissible.28 2 This position does not contend that children should be
precluded from participation in research; rather, until they can
autonomously consent to more serious self-sacrifices, they should not be
enrolled in placebo-controlled research when there is a more protective
approach, such as using active controls, which allows children to help
others while minimizing their own discomfort. 8 3
Children deserve stringent protection because they are not research
volunteers in the same sense that adult participants are. Every possible
281. Id. at 853.
282. But see, Carol Levine, Placebos and HIV: Lessons Learned 28(6) HASTINGS CTR.
REP. 43, 45 (1998), which notes that there is a utilitarian argument that would permit the use
of placebo controls despite the existence of safe and effective treatment for both adults and
children suffering from both serious and minor conditions based on the idea that the "most
efficient study is the most ethically sound." Id. On this rationale, placebos are always
permissible, despite the fact that they may risk the health, safety, and even lives, of some
subjects, because they will provide the most conclusive data in the fastest possible manner,
thus improving the lives of more individuals than were sacrificed.
283. See SHARAV ET AL., supra note 111 (indirectly examining children's inability to
self-sacrifice by emphasizing their incapacity to consent and society's consequent obligation
to protect their best interests).
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measure should be taken to ensure that their health and safety are
maximized-that research is in their best interest to the greatest extent
possible.284 Denial of safe and effective therapy in favor of placebos for
any condition will do no such thing. Therefore, child subjects should be
assured that the current best medical practice standards of treatment will be
compared to any new or experimental therapy, even if their parents might
be able to legally, if not morally, deny them that standard treatment outside
of the research context.
This section has explained the circumstances under which placebocontrolled clinical research is ethically permissible for both adults and
children. For all human subjects, placebos are appropriately used in trials
examining the safety and efficacy of drugs to treat a condition for which
there is currently no safe and effective treatment. However, once a safe and
effective therapy is available, the paths of adult and child subjects diverge.
Adults are generally competent individuals with the capacity to consent to a
wide variety of risks, so they may choose to enroll in placebo-controlled
trials. Denial of effective treatment in favor of placebo is ethically
permissible for adult subjects suffering from only mild conditions, although
it cannot be permitted for severe conditions due to the impact of those
conditions on the subject's autonomy and capacity to fully consent.
While it may be tempting to extend this consent/severity framework to
pediatric subjects by simply substituting parental permission for the child's
consent, this substitution is imperfect. Parents have no basis on which to
implement the choices they believe their children would make if competent,
and thus they must rely on a best interest standard that does not exist in
adult situations.
Parents cannot refuse safe and effective therapy for their children in lifethreatening situations in the context of standard care, regardless of religious
or other objections.
In addition, children, unlike adults, cannot
appropriately receive placebos rather than proven therapies for mild
conditions because any level of suffering or discomfort caused by such
denial could not further their best interests. 8 5 When there is a safe and
284. Rosato, supra note 30, at 367. This focus on a child's best interest is in line with
the bioethical principle of beneficence, which requires doing good and not doing harm, and
is the most important consideration in pediatric research given that autonomy is diminished
if not entirely nonexistent. Id.
285. There may be instances in which an individual who is legally still considered a
minor has full developmental autonomy to make choices for him or herself, in which case,
the best interest standard would no longer apply and the "child" should be treated as an adult
in the medical arena. Further, autonomy is not an all-or-nothing quality and children will
progressively develop more and more autonomy as they grow older. This article does
attempt to respect this developing autonomy by supporting the solicitation of child assent to
research participation and by not advocating a position that would completely bar a child's
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effective treatment for any condition afflicting a child, that alternative must
replace placebos as the control in order for research to be ethically sound.
Until such treatment exists, placebos remain ethically acceptable, thus
mirroring the legal requirements for pediatric placebo-controlled research
determined in Part IV above.
B. Application to FDA's Requests
Recall that while some drugs have been specifically labeled for the
treatment of pediatric OCD and depression, recent concerns have arisen
about the safety of all drugs used to treat these conditions due to data
demonstrating an increased risk of suicidality. Therefore, while certain
drugs may be effective for these indications, there is currently no treatment
that is both safe and effective. This fact renders the placebo controls
requested by the FDA ethically permissible at the current time, under the
generally uncontroversial analysis governing the use of placebo design
when no proven treatments could serve as an alternative. As the child
subject will not be denied any known safe treatment that he or she would
otherwise receive outside of the study, the child is not asked to accept
undue risks. Therefore, the interests of the general pediatric population do
not unfairly subsume the individual child's interests.
However, consider the argument that rejects this safety analysis because
so few children experience an increase in suicidal feelings while taking
these drugs. In fact, these drugs have not been taken off the market and are
still prescribed to children with black box warnings that instruct careful
monitoring. 86 In other words, the balance among safety, efficacy, and
severity of the condition may weigh in favor of a conclusion that these
drugs are more appropriate than placebo. Additionally, the use of a placebo
to study drugs that treat these conditions in children does not truly fall
within the "no safe and effective alternative" category because subjects
would be denied valuable treatment they might otherwise receive. Using
this approach or assuming the validity of the FDA's current requests, once
safety studies of Prozac, Zoloft, Luvox, or Anafranil rule out suicidality
concerns (or once an entirely new drug is approved), a safe and effective
alternative to placebo will exist, which triggers the more complex ethical
analysis outlined in Part V.A.3.
Clearly, it will not be in the best interest of any child to continue to suffer
from OCD or depression when a proven therapy exists; therefore, once that
enrollment in research because they cannot yet consent.
286. FDA, Labeling Change Request Letter for Antidepressant Medications,
http://www.fda.gov/cder/drug/antidepressants/SSRIlabelChange.htm (last visited Oct. 20,
2006).
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proven therapy arrives, the use of placebo controls will no longer be
justifiable and the FDA should stop requesting them. Future studies should
go forward in hopes of improving upon the existing standard of care, but
the FDA should request active-controlled studies in return for pediatric
exclusivity and require them under the PREA. Notably, the FDA should
request active-controlled studies even if one erroneously applies the
severity distinction to research on children. Pediatric OCD and depression
are certainly less severe than conditions like HIV and cancer, but it does not
follow that only life-threatening conditions should be considered serious
enough to prohibit subjects from enrolling in placebo-controlled research.
While some might categorize most non-suicidal psychiatric conditions,
including outpatient depression, OCD, panic disorder, and anxiety, as
sufficiently non-severe to permit study through placebo controls, the FDA
has recognized that depression and other psychiatric disorders in pediatric
patients can have serious consequences if not appropriately treated.2 87
Further, OCD has been described as a "chronic, often debilitating mental
disorder, causing intensely recurrent, unwanted thoughts, or obsessions,
usually coupled with uncontrollable, repetitive behaviors, or compulsions
that interfere with daily life,"2 88 and depression is
characterized by long duration, and is associated with insomnia,
irritability, changes in eating habits, and severe impairment of the child's
scholastic and social adjustment. Depression should be considered
whenever any behavior problem persists. Depression does not refer to
transitory moments of sadness, but rather to a disorder that affects
development and interferes with realization of the child's innate
potential. Some manifestations of depression in a school-aged child
include anorexia, lethargy, sad affect, aggression, weeping, hyperactivity,
somatization, fear of death, frustration, feelings of sadness or
hopelessness, self criticism, frequent day dreaming, low self-esteem,
school refusal, learning problems, slow movements, vacillating hostility
towards parents and teachers, and loss of interest in previously
pleasurable activities.289
Clearly, these conditions are not mild and they are associated with more
than mere discomfort in children. Therefore, both the severity and best
interest standards will prevent placebo-controlled research on OCD and
287. Press Release, supra note 172.
288. Melissa Tennen, Therapy, Meds Can Help OCD Kids, HEALTH A TO Z (June 2005),
http://www.healthatoz.com/healthatoz/Atoz/dc/cen/ment/obcd/
at
available
alertO1202004.jsp (last visited Nov. 9, 2005).
289. Nat'l Cancer Inst., Pediatric Considerations for Depression, available at
http://www.nci.nih.gov/cancertopics/pdq/supportivecare/depression/healthprofessiona/allpa
ges#Section_243 (last visited Nov. 9, 2005).
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depression in children, even if it might be permissible when no undeniably
safe treatment exists.
Although placebo controls might help answer research questions more
efficiently, when they deny proven therapies they do so at the expense and
suffering of some human subjects. While adults can personally consent to
some level of suffering for the purpose of research, even when there is a
safe and effective therapy available for their condition, children cannot and
alternatives to placebos should be utilized whenever possible. Therefore,
the FDA should amend its written request templates for studies of OCD
drugs and antidepressants in children so that holders of approved
will perform only head-to-head trials once a proven treatment
applications
2 90
exists.
CONCLUSION

This article has demonstrated the dire need for pediatric research and has
chronicled several FDA attempts to encourage, and eventually require,
sponsors to test their drugs for safety and efficacy in children. Under the
Best Pharmaceuticals for Children Act, the FDA makes specific requests for
placebo-controlled studies of drugs to treat OCD and depression in children.
The FDA has continued to make these requests even after a handful of
drugs were specifically approved for those indications. However, this was
before the recent suicidality concerns associated with these drugs came to
light, indicating that the conclusions reached in this article are a far cry
from current FDA policy.
While these requests are probably legally approvable and ethically
permissible at the moment, assuming that the suicidality issue creates a
situation where there is no safe and effective alternative to placebo, the
analysis will change as these suicidality concerns are overcome. At that
point in time, the relation of the anticipated benefit to the risk of placebo
will no longer be at least as favorable to the subjects as that presented by
available alternative approaches. The risk posed by the use of placebo
would not be categorized as only a minor increase over minimal risk
because it would no longer be equivalent to the level of risk that children
suffering from the condition are exposed to outside of the research setting.
The studies could not be approved under the minimal risk or catchall
290. Charles Weijer, Ethical Concerns in Pediatric Placeboa-Controlled Trials,
Meeting of the FDA's Pediatric Subcommittee of the Anti-Infective Drugs Advisory
Committee, Sept. 11, 2000, 81 http://www.fda.gov/ohrms/dockets/ac/00/transcripts/
3641tl.pdf. (stating "[a]fter placebo-controlled trials have demonstrated a treatment to be
effective for a particular patient population, for second generation treatment, the comparator
must be an active control.").
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categories, and thus the FDA's requests would be legally impermissible
under Subpart D. Similarly, the inapplicability of the severity distinction
used to justify placebo controls for mild conditions in adult subjects and the
applicability of the stringent best interest standard renders the use of
placebo over proven therapies ethically unacceptable. This conclusion rings
true regardless of whether parents have the freedom to refuse these
treatments for their children in the context of clinical care.
Pediatric research is necessary to protect children from the unavoidable
daily experimentation that occurs when their doctors lack information about
whether the drugs available for adults will behave similarly in all age
groups. Controlled clinical trials are the only valid way to develop the
knowledge base that pediatricians need. Placebos offer many advantages,
but their efficiency and the clarity of their results cannot always justify their
use in pediatric subjects. Now that protective inclusion of children in
research is on the rise because of several laudable interventions from
Congress and the FDA, protective exclusion will also become increasingly
important. When a safe and effective treatment for the pediatric indication
under study exists, the FDA must request and require proven therapy to
serve as an active control. Under this proposal, doctors will still receive
their desperately needed prescribing information and children will be
protected both in the clinical setting and in research.
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